#version: 0.2
i n
t i
r e
t h
a n
e n
e r
e d</w>
o n
o f</w>
a t
th e</w>
r o
i n</w>
a ti
i t
an d</w>
a r
o n</w>
s t
s i
a l
a l</w>
o r
i c
a s
e c
d i
a c
en t
l o
in g</w>
t o</w>
o r</w>
u r
e r</w>
a s</w>
a m
e s
c o
w it
u l
wit h</w>
o l
d e
s e
u c
in e</w>
re s
p h
en t</w>
l e
l y</w>
ati on</w>
r i
v e</w>
c on
p ati
w as</w>
p ro
e s</w>
o u
T h
d uc
er e</w>
c h
m e
v e
at ed</w>
s .</w>
i d
f f
r a
o s
o c
i s</w>
a n</w>
p er
i c</w>
u s
a t</w>
ent s</w>
a g
i m
o t
a d
h e
w ere</w>
i l
ti on</w>
s u
a p
u n
co m
c e
p a
duc ed</w>
f or</w>
b e
t re
ec t
n e
i s
Th e</w>
t er
e x
b y</w>
re n
in e
p l
pati ents</w>
a b
v er
r at
e ff
t o
e m
in duced</w>
ati on
it y</w>
h i
d o
in c
h y
w e
th at</w>
e n</w>
p res
s ,</w>
n o
re as
t er</w>
h a
c e</w>
t e
a r</w>
re d</w>
m in
a f
u d
m ent</w>
ti on
g n
l i
con t
u t
m a
r an
s y
- induced</w>
i f
an t
p re
v i
l e</w>
h o
c ar
at e</w>
ti c</w>
af ter</w>
ti ve</w>
c a
w h
p or
y .</w>
tre at
ic al</w>
r u
c l
th er
m o
i st
p o
0 .
si on</w>
b e</w>
q u
on e</w>
si gn
m or
no t</w>
g /
or m
as e</w>
) .</w>
e d
y ,</w>
an t</w>
o m
as s
g h
i z
ro u
p ar
inc reas
d a
u m
p i
eff ect
in f
ul ar</w>
u m</w>
th e
) ,</w>
if ic
m on
e t
os e</w>
e v
y l
ther ap
s er
si s</w>
ur e</w>
in t
re ce
in g
ti v
c or
d ru
s e</w>
f i
lo w
i o
d ur
lo g
I n</w>
th er</w>
g en
sign ific
o x
st ud
m ic
an ti
treat ment</w>
ou s</w>
s ho
oc i
b u
ar e</w>
an g
m g/
en ce</w>
o b
e st
u s</w>
u re
ro m</w>
min ist
v ed</w>
ti c
pa th
l l
effect s</w>
lo p
al ly</w>
ec t</w>
to x
e .</w>
ent r
u ro
f rom</w>
in d
be t
res p
ass oci
p t
ad minist
th is</w>
i a</w>
tre ated</w>
di s
us e</w>
g rou
car di
si on
un c
es e</w>
re l
ha d</w>
de ve
ation s</w>
e l
ul t
e ar
e ,</w>
su b
ac tiv
t en
b lo
hy per
ro m
ren al</w>
ar y</w>
am ine</w>
S :</w>
deve lop
ot en
f ol
e p
w i
re por
dur ing</w>
ve l
ti m
associ ated</w>
th an</w>
stud y</w>
cont ro
+ /
ne uro
us ed</w>
rat s</w>
hi b
d ose</w>
y c
pati ent
d er
am in
ag e</w>
d .</w>
t ran
r on
m ent
y s
r ac
a z
O N
ou n
d e</w>
o log
g h</w>
c ur
wi th
tox ic
bu t</w>
si ve</w>
f unc
ut e</w>
d ec
r ation</w>
eff ect</w>
es t</w>
p os
p en
n orm
ma y</w>
l l</w>
es s</w>
es .</w>
ati ve</w>
1 0
in j
in hib
su g
p oten
se s</w>
ec tive</w>
c i
s p
b o
0. 0
fol low
u di
t ed</w>
be en</w>
sug g
g ra
we e
i d</w>
w he
resp on
o d</w>
c entr
pro te
tran s
ha ve</w>
or y</w>
W e</w>
wh o</w>
mg/ k
me th
v en
dec reas
al u
pres s
an ce</w>
a in
l u
increas ed</w>
an c
sho w
g i
ff e
al l</w>
sy n
+/ -</w>
therap y</w>
st udi
in v
en c
rece i
in ter
da y
re qu
ch ang
id e</w>
ation .</w>
y ear
o l</w>
com p
cl in
ul d</w>
signific ant
res ult
i ti
er g
dru g</w>
administ ration</w>
ri s
i r
i a
al l
v er</w>
s ec
mic ro
Th is</w>
rece pt
ar di
pati ent</w>
ac t
a st
ine -induced</w>
ect ed</w>
ac ute</w>
ou t</w>
le vel
l on
ec h
dru g
ob ser
n o</w>
me di
es ,</w>
d er</w>
a il
ot h</w>
significant ly</w>
m y
ic h</w>
h as</w>
( 1
we en</w>
s en
p e
hi gh
c al
wh ich</w>
f orm
bet ween</w>
a k
ve n</w>
grou p
re e</w>
pa red</w>
ine .</w>
p to
i gh
duc tion</w>
ch em
te st
he ar
ch ol
ab le</w>
th ese</w>
int ra
inhib it
id ence</w>
ed .</w>
t w
t ri
di se
si b
ffe ren
es s
activ ity</w>
ar i
develop ed</w>
al o
wee k
re at
ec tion</w>
b ra
com pared</w>
E S
pl ic
tion .</w>
ti al</w>
signific ant</w>
s o</w>
r am
mor e</w>
g lo
al y
c ase</w>
tion s</w>
norm al</w>
b oth</w>
b l
rat e</w>
l im
di fferen
clin ical</w>
re g
p ri
or s</w>
c as
5 -
1 .
v as
m s</w>
do p
blo od</w>
ag on
show ed</w>
s t</w>
m at
an d
u sion</w>
se iz
ris k</w>
pl as
ph a
oc cur
f or
f ail
oc ardi
co ca
b in
toxic ity</w>
rel ated</w>
it s</w>
i t</w>
i al</w>
grou p</w>
con centr
t s</w>
m a</w>
lon g
ex per
st er
ph en
1 0</w>
lo s
he pati
g l
di d</w>
I ON
ti s</w>
t y
sy m
st r
ou r</w>
mor ph
m il
m al
d ys
ch ron
at ing</w>
al so</w>
( 2
se l
rat s.</w>
ol y
level s</w>
fi r
ou s
o ther</w>
mon th
ev alu
E T
A C
' s</w>
se v
ind ic
follow ing</w>
d ro
contro l</w>
C L
ul ation</w>
oun d</w>
m an
ec ti
sy st
mo de
il e</w>
func tion</w>
f requ
day s</w>
ar ter
Th ese</w>
L T
y m
si de</w>
me t
m un
iz ed</w>
erg ic</w>
e -
de f
whe n</w>
th rom
ol d</w>
le v
ech an
d u
cardi a
U S
% )</w>
ver se</w>
ver ,</w>
tw o</w>
su p
re c
or al</w>
ne ph
lo w</w>
d ic
cont in
c ular</w>
blo c
an e
0 0</w>
st o
path y</w>
mg/k g</w>
m g</w>
m echan
olog ical</w>
increas e</w>
b as
al pha
n it
u se
t ac
obser ved</w>
er s</w>
da y</w>
d am
c ri
at ri
2 .
ure s</w>
treat ment
ti g
si st
il ity</w>
hyper ten
th i
sym pto
on ly</w>
l ess</w>
de ter
chron ic</w>
ar k
result s</w>
re f
os t</w>
me as
m er
ar g
US ION
ON CL
ONCL USION
M ET
H O
C ONCLUSION
si a</w>
prote in
o ph
it y.</w>
ine ,</w>
gen er
d y
cas es</w>
I n
5 0</w>
ver y</w>
v ari
us ing</w>
sugg est</w>
s uc
mechan is
hy poten
ex pos
enc y</w>
sib le</w>
sho uld</w>
s ti
r al</w>
hear t</w>
ed ,</w>
decreas ed</w>
com bin
ation ,</w>
al s</w>
ac et
v ing</w>
re t
es tig
de pen
c y
5 %</w>
tion ,</w>
sev ere</w>
s ur
respon se</w>
press ure</w>
n on
contin u
bloc k
ant agon
ac e
a x
3 .
pa in</w>
o di
inv estig
ca used</w>
w e</w>
u b
re ac
my ocardi
l ud
im mun
contro l
am i
U LT
R ES
RES ULT
2 -
with out</w>
pres ent</w>
neph ro
m i
l at
depen d
ar c
RESULT S:</w>
t h</w>
sugg est
ser um</w>
m ost</w>
inc lud
igh t</w>
f ound</w>
we ver,</w>
t e</w>
studi es</w>
sen si
s h
e th
MET HO
METHO D
u p
tion al</w>
th ou
s al
repor t</w>
re co
oc y
in .</w>
en ce
do ses</w>
th ose</w>
pres sion</w>
p at
i r</w>
glo mer
repor ted</w>
recei ved</w>
pro t
li ver</w>
ine -
ce ll
am ph
ad verse</w>
5 0
sec on
recept or</w>
in -
i .
ha vi
f act
cardia c</w>
re duced</w>
p er</w>
in ,</w>
il l
ic i
f e
chang es</w>
trans pl
thou gh</w>
sion .</w>
plas ma</w>
per io
patient s.</w>
p sy
ous ly</w>
is o
fir st</w>
comp le
com m
an aly
v entr
ti s
p le
meth yl
ma in
gi ven</w>
d ing</w>
com plic
c yc
be havi
b io
un der
therap y.</w>
si s.</w>
re ,</w>
ou t
inf usion</w>
g e
do se
d es
d ed</w>
an im
P A
week s</w>
ventr ic
pre v
per form
myocardi al</w>
ing s</w>
gra ph
exper im
car b
vas cular</w>
th ree</w>
ro lim
n ec
hi gh</w>
f ind
d rom
c an</w>
3 0</w>
( A
ur ia</w>
ty p
re duction</w>
ot or</w>
me an</w>
ic ot
for e</w>
ex amin
es the
duc e</w>
du e</w>
d -
- old</w>
tim e</w>
pres ent
os ph
m ac
e red</w>
METHOD S:</w>
L -
2 0</w>
ventric ular</w>
ven ous</w>
syn drom
si mil
se ver
resp ecti
pl ace
p it
m it
e pi
d at
bet a
inj ection</w>
im pro
i p
g res
f lu
ect s</w>
cardi o
a v
- 1
v it
u p</w>
ren t</w>
r h
per id
me n</w>
l it
em ia</w>
dise ase</w>
ati c</w>
amph et
E C
A l
the ir</w>
sion ,</w>
s )</w>
r ine</w>
m ark
inv ol
inc idence</w>
hy po
ex t
dise as
bra in</w>
ac id</w>
4 .
( P
we ll</w>
ur al</w>
ter m</w>
st ri
si de
re ver
por t
ph osph
n icot
in iti
high er</w>
fi b
fail ure</w>
er al</w>
di ag
d s</w>
coca ine</w>
ve l</w>
ur ther</w>
syndrom e</w>
suc h</w>
s tim
s co
respecti vel
m us
li k
g ram
ent ly</w>
el ect
do m
chem o
ce ll</w>
b le
ain ed</w>
administ ered</w>
2 0
ve ly</w>
recei ving</w>
ra di
patient s,</w>
in al</w>
im pa
ia .</w>
hy dro
hi st
d ,</w>
c in
c anc
T I
v alu
ra t</w>
p ul
mic e</w>
ia ,</w>
i ther</w>
e lev
d ra
c ap
at e
ar ac
a ff
( C
throm bo
po st
p y
ol ic</w>
norm al
g en</w>
ence ph
dop amine</w>
az ol
at al</w>
R O
0.0 0
ure .</w>
u red</w>
sub j
re b
re as</w>
psy ch
pre vi
is t</w>
h alo
epi le
en z
en ti
dur ation</w>
dra w
de mon
c lo
ati n</w>
H o
4 -
y -
u al</w>
t ot
simil ar</w>
s ing
re ve
re main
om e</w>
it y,</w>
g e</w>
f t</w>
f er
ent al</w>
b ut
ac tion</w>
a y
U N
N a
I t</w>
1 2</w>
year -old</w>
y si
with in</w>
v al
sion s</w>
se qu
ro le</w>
p r
ox id
occur red</w>
mg/k g
m ents</w>
inf arc
in to</w>
drug s</w>
develop ment</w>
at es</w>
ang io
ad di
ab ility</w>
x im
v ol
ran dom
o p
le ar
l as
in ine</w>
e ither</w>
depend ent</w>
c um
be fore</w>
ad ren
a in</w>
Ho wever,</w>
H B
) -
with draw
w ar
per i
no w
low er</w>
dis or
concentr ations</w>
com par
ca use</w>
a d</w>
T o</w>
N A</w>
A T
2 4</w>
( n</w>
( 3
wh ile</w>
ul t</w>
studi ed</w>
si s,</w>
s ul
reve al
pro long
pro gres
perform ed</w>
ox ic
o ver</w>
month s</w>
mode l</w>
l y,</w>
k now
e u
dat a</w>
centr al</w>
cal c
ass ess
an y</w>
CONCLUSION S:</w>
A n
7 .
treatment .</w>
t ing</w>
sympto ms</w>
rolim us</w>
olog ic</w>
o id
meas ured</w>
l in
id ine</w>
elect ro
eff ective</w>
alpha -
al ge
ab s
a ine</w>
a .</w>
a ,</w>
E :</w>
yc in</w>
v ul
uc le
tox ic</w>
sel ective</w>
poten tial</w>
p ol
n er
ho ur
gh t</w>
f em
en h
decreas e</w>
dam age</w>
con cl
chol est
c is
ar mac
K G
A M
1 9
1 -
- term</w>
w o
syst em
s am
reveal ed</w>
p p
ol er
o f
morph ine</w>
m ul
m in</w>
is h
find ings</w>
c reat
RO UN
KG ROUN
B AC
BAC KGROUN
A f
wee k</w>
transpl ant
t est</w>
sp ec
s on
ren ce</w>
o ver
mic e.</w>
m is
k ine
he pat
f urther</w>
er o
en do
des cri
d os
combin ation</w>
co uld</w>
cl on
beta -
bas el
5 .
3 -
10 0</w>
( P</w>
str uc
st at
sing le</w>
ro s
prolong ed</w>
on t
non -
me mor
mal e</w>
li thi
id ne
ic in</w>
ic ally</w>
hepati tis</w>
de t
con vul
az ep
arac ter
a u
BACKGROUN D
6 0</w>
0 -
se t</w>
reb ral</w>
protein uria</w>
pro l
ph ysi
on g</w>
n a
me dic
lo com
increas es</w>
in -induced</w>
i red</w>
hypoten sion</w>
f our</w>
bl ad
ar b
a use</w>
v id
ti n</w>
t em
po si
par tic
k idne
i l</w>
halo perid
g reat
f ar
ev idence</w>
ec ause</w>
differen t</w>
deter min
concentr ation</w>
ch aracter
anim als</w>
ab ol
T w
BACKGROUND :</w>
Af ter</w>
1 5</w>
year s</w>
tis su
tic al</w>
th al
t u
t oler
s y</w>
s af
pl e</w>
ox y
om a</w>
micro gram
ma j
inj ur
i tion</w>
group s</w>
f u
et y</w>
epile p
car cin
at ten
at ory</w>
ain ing</w>
ac h</w>
P ati
9 5%</w>
0.0 5
ur on
th rou
t ak
si x</w>
seiz ures</w>
s ome</w>
s ed</w>
p .
odi um</w>
nit ro
mode l
int rac
ing ,</w>
im port
fem al
f o
dis continu
di st
comm on</w>
co ur
chang e</w>
cell s</w>
am p
a y</w>
S R
% ,</w>
ve ment</w>
tot al</w>
ri am
re pe
re duc
prote in</w>
per ative</w>
ot oxic
mg/ m
li al</w>
l y
intra venous</w>
inj ec
high -
he mo
gen e
g u
flu o
f ac
ex pression</w>
c ess
bra dy
ap pe
ane ous</w>
a ver
Pati ents</w>
4 0</w>
- 1</w>
w om
u lo
typ e</w>
therap eu
th ere</w>
tac hy
t ra
pro duced</w>
place b
placeb o</w>
p ra
p ac
or t
m b
lo c
l ine</w>
k ed</w>
in ary</w>
il d
h um
experim ental</w>
e t</w>
e m</w>
de s</w>
cardi a</w>
basel ine</w>
assess ed</w>
am ide</w>
P )</w>
C A
whe reas</w>
us ,</w>
ter n
s it
re le
on ary</w>
o id</w>
ne g
n ing</w>
min ut
memor y</w>
medi an</w>
m l
le vel</w>
includ ing</w>
great er</w>
glomer ular</w>
en s
d y</w>
co un
blad der</w>
arter y</w>
ant s</w>
anc ed</w>
an s</w>
am in</w>
am eth
Th ere</w>
TI V
O n
w or
vi v
v ast
su ff
s odium</w>
re gi
re cur
re cor
r in</w>
per c
par t
ne uron
mor rh
mechanis ms</w>
m ou
m ic</w>
inhibit or</w>
inf u
i tive</w>
hyperten sion</w>
he morrh
exper i
er y
d ou
chemo therapy</w>
ch ild
cardio vascular</w>
canc er</w>
ca u
bo dy</w>
arter ial</w>
an esthe
an ce
a vi
EC TIV
A d
therapeu tic</w>
result ed</w>
ph armac
p ine</w>
or g
on e
nicot ine</w>
locom otor</w>
iti es</w>
ing .</w>
indic ate</w>
i ly</w>
hepati c</w>
gl ut
g o
em ent</w>
di ff
de press
da ily</w>
con sist
cl ero
as t</w>
antagon ist</w>
am e
a w
O B
OB J
OBJ ECTIV
I I</w>
1 3</w>
1 2
vit amin</w>
v ac
ud e</w>
tiv ity</w>
struc t
st ro
r hy
rhy th
pri or</w>
poten ti
pos sible</w>
os pit
me mb
m ol
it ed</w>
ish ed</w>
im en
im ag
id oc
he m
he al
expos ure</w>
cont rac
co gn
cis pl
ap p
analy sis</w>
am ong</w>
ab l
CONCLUSION :</w>
Al though</w>
1 ).</w>
( S
% ).</w>
withdraw al</w>
vi e
u res
ti co
sur g
ster one</w>
reco very</w>
recept or
rat s,</w>
r it
pi d</w>
perio d</w>
p tion</w>
on set</w>
o st
o graph
mul ti
mo d
maj or</w>
m R
long -term</w>
l or
k g
k e
in son
in duc
in d</w>
id enti
follow ed</w>
follow -
fi ve</w>
examin ed</w>
evalu ated</w>
c it
b il
b en
atri al</w>
A ll</w>
6 .
( 0.
z e</w>
toxic ity.</w>
throu gh</w>
stim ul
st rat
ser i
s us
re d.</w>
mon it
memb ran
m ine</w>
lik e</w>
le ft</w>
l idoc
know n</w>
iz ation</w>
in s</w>
hear ing</w>
h e</w>
frequ ency</w>
er ,</w>
enceph alo
diag no
cor onary</w>
con di
cogn itive</w>
co ll
cal ci
c at
at ro
ap pro
ag ents</w>
ad j
T R
N e
D e
C I
A N
6 -
1 3
- H
+/ -
( -
v ud
um b
u r</w>
ti s.</w>
the sis</w>
sever ity</w>
remain ed</w>
pro duc
previ ously</w>
prev ent
pres ence</w>
pre gn
ob t
nec ro
met abol
medi ated</w>
los s</w>
ll ed</w>
lithi um</w>
is m</w>
inhib ition</w>
i de
hem oly
ha em
e p</w>
disor der
diseas e.</w>
di vid
cyc lo
cy to
cor rel
con ver
at ed.</w>
ang i
al though</w>
al .</w>
ag ain
ac id
Th e
P ro
M A
C om
C h
yl chol
y l</w>
t r
stud y,</w>
sensi tivity</w>
secon d</w>
s ol
s le
ri b
posi tive</w>
path y.</w>
oten s
on d
na use
mechanis m</w>
m g
m ag
includ ed</w>
impa ir
hour s</w>
heal th
fact or</w>
f ul
f ree</w>
dys kine
di rec
creat inine</w>
b in</w>
ati s
an e</w>
amphet am
al ,</w>
ad riam
ab normal
M D
B A
8 .
1 )</w>
wo men</w>
treatment ,</w>
ti l
ti es</w>
the lial</w>
suggest s</w>
st ar
st and
si m
si c</w>
show n</w>
ro w
recept ors</w>
re sist
psych o
prote ren
ph rine</w>
ph eral</w>
p oly
o ch
m m
m en
is ol
investig ated</w>
in o
immun o
ic ep
ic ac
g am
fluo ro
expos ed</w>
ev o
enz ym
ens ity</w>
dou ble
dose -
dop a</w>
dis c
di a
de l
con f
angi otens
ak e</w>
again st</w>
a th
G rou
C a
2 7
2 ,</w>
- treated</w>
( N
( D
x ameth
ure ,</w>
ti z
ti d
stud y.</w>
stat us</w>
st ra
sen s
py ri
pri m
olog y</w>
n umb
n ucle
ma xim
lo l</w>
le u
k ing</w>
infarc tion</w>
import ant</w>
hum an</w>
he mat
gl yc
fi ed</w>
femal e</w>
ev ents</w>
ery th
dys function</w>
dys func
double -
d oc
cor tico
comple te</w>
ch lor
c es</w>
c er
ar ly</w>
ar d</w>
an emia</w>
amphet amine</w>
ami de
abs ence</w>
ab le
OBJECTIV E:</w>
E P
A c
1 1</w>
( T
( 6
whe ther</w>
ver su
versu s</w>
ty -
tic ally</w>
t en</w>
str ated</w>
seiz ure</w>
s hi
s :</w>
ri al</w>
res ult</w>
present ed</w>
pos sib
pl us</w>
p ent
och ond
oc amp
neuro log
me .</w>
m ia</w>
m as
m .</w>
iso proteren
injur y</w>
inf lu
in ic</w>
hyper alge
h ospit
glut am
gener ation</w>
gen ic</w>
g ran
follow- up</w>
f ic
eff icac
determin ed</w>
deter mine</w>
c re
behavi oral</w>
b ac
ar rhyth
an a
ag ent</w>
ac tin</w>
Tw o</w>
M R
M P
6 %</w>
) ;</w>
wit ch
w il
suggest ed</w>
sub st
s o
s ;</w>
s /
s -
rever sible</w>
reg imen
re s</w>
prot ective</w>
pp ocamp
peri pheral</w>
p ot
on e,</w>
n os
mon ary</w>
ment al</w>
me d
mR NA</w>
m ight</w>
l y.</w>
is on</w>
inhibit ors</w>
hi ppocamp
func tional</w>
ev ent
ep iso
control s</w>
cont aining</w>
calci um</w>
azol e</w>
azep ine</w>
ation s.</w>
associ ation</w>
ami vud
ag es</w>
ag e,</w>
activ ation</w>
ab ly</w>
P G
I V</w>
I I
HB V</w>
1 ,</w>
0 %</w>
we igh
valu es</w>
ur inary</w>
un der</w>
tissu e</w>
suff ici
su al</w>
st atis
sp ont
sign s</w>
se d.</w>
s mo
s m
ri c</w>
rele ase</w>
rat ory</w>
ran ge</w>
pi ratory</w>
otoxic ity</w>
ot on
oc icep
mi gra
los por
lo ro
l ym
l ur
inj ected</w>
health y</w>
g row
experi enc
e ly</w>
e ach</w>
diag nos
demon strated</w>
complic ation</w>
com it
c ul
c an
bio p
b ecause</w>
ate ly</w>
arb it
ap o
and /
and/ or</w>
all y,</w>
al ity</w>
al ine</w>
ag ed</w>
ag e.</w>
ac tive</w>
R e
I m
I N
G F
B C
9 .
. )</w>
( p</w>
x i
v s.</w>
use .</w>
u st
tran si
tim es</w>
tic s</w>
t um
t .</w>
t ,</w>
subj ects</w>
stim ulation</w>
seiz ures
secon d
se x
se en</w>
sam e</w>
s ch
respon ses</w>
res ol
r ati
pul monary</w>
pro p
po sto
pi vac
out com
on ic</w>
ol -induced</w>
obt ained</w>
obser v
ob arbit
mit ochond
m m</w>
lym ph
log ra
lit er
liter at
lidoc aine</w>
leu k
inter v
in duction</w>
in duce</w>
ific ation</w>
i or</w>
hydro x
gam ma
for m</w>
f rac
ex ten
evo ked</w>
er .</w>
em b
elev ated</w>
ear ly</w>
e ven</w>
double- bl
do x
differen ces</w>
cyclo phosph
cyc lospor
cont ra
combin ed</w>
chem ical</w>
ch an
chan ne
ce rebral</w>
carb am
c lear
c es
be ing</w>
amin o
administ r
ad v
ab out</w>
T A
T )</w>
On e</w>
E ff
D )</w>
3 ,</w>
1 7
1 6</w>
1 4</w>
y p
y o
vol um
transpl ant</w>
test ed</w>
t rac
syst olic</w>
syst em</w>
syn dro
sle ep</w>
sign ed</w>
sever al</w>
s a
ret ur
respectivel y.</w>
res piratory</w>
pres su
pre dic
place bo
pi lo
os up
on e.</w>
ocy te</w>
numb er</w>
n am
mus c
me tid
me ,</w>
m an</w>
invol ved</w>
initi al</w>
in ergic</w>
i ed</w>
ho wever,</w>
hi sto
he ad
haloperid ol</w>
fe at
eryth ro
er s.</w>
epilep tic</w>
dose .</w>
do g
disc us
def ici
con comit
ce p
ay s</w>
app ear
ap ine</w>
antagon ist
al one</w>
ag ent
aff ected</w>
ab or
ab il
P re
P ark
N o</w>
C on
C O
6 ,</w>
( n
( 5
% .</w>
% ),</w>
y e
wom an</w>
ur ing</w>
ur ac
under ly
underly ing</w>
tri al</w>
test s</w>
tak ing</w>
sympto m
surg er
sup por
su m
str ic
ster oid
spec if
specif ic</w>
second ary</w>
sec re
saf ety</w>
ri ght</w>
ri g
reac tions</w>
re st
re .</w>
ran g
prol actin</w>
pres sive</w>
pr amine</w>
ph ase</w>
path y,</w>
p ur
neg ative</w>
n ot
ment .</w>
ma int
m ut
l amivud
l am
kidne y</w>
inhibit or
immun osup
im medi
il t
i. p.
hyperten sive</w>
g re
g ast
frequ ent</w>
form ation</w>
far in</w>
fact ors</w>
f oc
efficac y</w>
e qu
dy nam
do es</w>
di aly
de ple
day s.</w>
control s.</w>
ci metid
c ros
atri c</w>
as si
ane ur
ana esthe
adren ergic</w>
ad en
T E
S i
R ec
Park inson
H e
2 1</w>
10 -
1 4
( 4
ye ar</w>
y ro
y oun
vi sual</w>
vast atin</w>
tum or</w>
tre m
ter s</w>
tem por
t ub
t ro
stro k
si rolimus</w>
sensi tive</w>
sco pol
ri ll
re vie
pro b
pre treatment</w>
phen y
p ap
ox if
ocardi ograph
o re
neuro pathy</w>
ner ve</w>
m id
lik ely</w>
impro ved</w>
impa ired</w>
i. v
i f</w>
ho l</w>
group s.</w>
glutam ate</w>
gene sis</w>
fu l</w>
es tim
er ing</w>
effect s.</w>
e very</w>
diagno sis</w>
def ic
de si
cour se</w>
con side
clo z
ci r
ca ffe
c ess</w>
bu pivac
b le</w>
atten u
at h</w>
at eral</w>
at e,</w>
anti depress
aneur ys
amin oph
al co
addi tion</w>
ac cum
S )</w>
O f</w>
K 50
H C
F K50
D O
C R
1 8
1 7</w>
1 ),</w>
tion s.</w>
ti s,</w>
thrombo tic</w>
te d.</w>
t -
system ic</w>
sul f
sub sequ
stri at
st ate</w>
sp inal</w>
si a.</w>
sho w</w>
ser oton
sal ine</w>
s witch
ri pt
ran ial</w>
pro duce</w>
pro ce
pra z
p u
or t</w>
on i
ol e</w>
of ten</w>
o sterone</w>
ne w</w>
ne ed</w>
n ess</w>
multi ple</w>
mou se</w>
mitochond rial</w>
mg/kg )</w>
mg/ d
lit ax
le sions</w>
l arg
it e</w>
is tic</w>
io d
inter sti
inhibit ed</w>
influ ence</w>
inf lam
in divid
im plic
i g
high- dose</w>
hemoly tic</w>
he par
glyc er
fib rill
fail ure.</w>
f low</w>
enh anced</w>
endo thelial</w>
enceph al
ecti vely</w>
e ll
do min
differen ce</w>
de ath</w>
cur rent</w>
contra st
com mon
cholest er
chol inergic</w>
cau ses</w>
calc ification</w>
c T
cT n
b rom
b ed</w>
au to
ati vely</w>
ar th
ap pa
an ic</w>
adj ust
ad e</w>
a thi
W he
T reat
R D
Parkinson 's</w>
P h
A D
5 5
5 ,</w>
2 5</w>
. ,</w>
z ed</w>
ylchol ine</w>
we ight</w>
vari ous</w>
ut aneous</w>
us ers</w>
ur ine</w>
un d
the tic</w>
tachy cardia</w>
t ly</w>
stand ard</w>
st res
si ze</w>
se ven</w>
se g
se d
se .</w>
ri tis</w>
repor ts</w>
reac tion</w>
re comm
pres cri
pre -
pilo car
par tial</w>
ocy to
oc c
no vel</w>
month s.</w>
mis sion</w>
minut es</w>
ma .</w>
m otor</w>
le ad
k in
ist ar</w>
investig ate</w>
intersti tial</w>
indic ating</w>
in sti
imag ing</w>
ic ill
i m</w>
head ac
group .</w>
glomer ul
gl y
experienc ed</w>
enzym e</w>
ent an
en e</w>
en d</w>
ech ocardiograph
e pa
e di
drug .</w>
direc t</w>
contro lled</w>
cont r
complic ations</w>
co -
cispl atin</w>
c h</w>
ay ed</w>
aver age</w>
as e,</w>
ap ri
am oun
al logra
ac hi
a sis</w>
a m</w>
W istar</w>
O ur</w>
I C
D i
D F
D -
C lin
A n</w>
A L
7 -
3 4
2 )</w>
( p
( B
y s</w>
y n
volum e</w>
ver ap
ve ,</w>
um ,</w>
u tive</w>
u s.</w>
u ally</w>
therap y,</w>
ther os
theros clero
the y</w>
th ir
th en</w>
tac rolimus</w>
t es</w>
suggest ing</w>
st on
st e
shi p</w>
s cor
s ),</w>
rever sed</w>
ref o
refo re,</w>
re n</w>
random ized</w>
progres sive</w>
pro v
pro f
posto perative</w>
pl ate
plate le
phen yl
phen obarbit
ph yl
pac litax
p id
or ub
on s</w>
nause a</w>
n or
model s</w>
mo der
min im
micro angio
li f
lev o
l abor
is chem
iod ar
ilt ration</w>
id ity</w>
id al</w>
hyper activity</w>
grow th</w>
glo bin</w>
f ron
ext rac
ex pl
epa m</w>
en ge</w>
e l</w>
di et</w>
descri be</w>
conside red</w>
con sum
comple te
clon idine</w>
child ren</w>
channe l</w>
carcin o
carbam azepine</w>
c ys
be ll
b ar
av oid
ation ship</w>
at ed
an alge
amin ergic</w>
a de
N O
Grou p</w>
D 2</w>
C l
8 0
2 5
(1 0</w>
( V
w ho
who m</w>
vi ral</w>
ve red</w>
ve d.</w>
ve .</w>
val pro
ur b
ud ed</w>
u tion</w>
u pt
transi ent</w>
til ity</w>
struct ural</w>
statis tically</w>
sm all</w>
sh ort
seri ous</w>
se ,</w>
ru s</w>
respectivel y,</w>
repe ated</w>
rel ationship</w>
reg ar
re duce</w>
rat .</w>
ra pid</w>
qu anti
prol act
pr us
perc ent</w>
path o
path ic</w>
partic ip
p ic</w>
p ec
ol ,</w>
ocicep tive</w>
o d
o -
neurolog ical</w>
neuro toxicity</w>
nec ess
n ed</w>
met ast
membran e</w>
med ical</w>
man if
low -
l un
inter ac
ine phrine</w>
increas ing</w>
impair ment</w>
hemorrh age</w>
h er</w>
g est
g ent
frequ ently</w>
feat ures</w>
ext ra
examin ation</w>
evalu ate</w>
ev ed</w>
en ing</w>
en g
ell ular</w>
el der
effect s,</w>
e rebral</w>
drug -induced</w>
double-bl ind</w>
di l
develop ing</w>
cor related</w>
concomit ant</w>
con fir
coca ine-induced</w>
ben e
bas ed</w>
b ul
b enz
ass ess</w>
as one</w>
arg inine</w>
appe a
angiotens in</w>
am ine
ag ic</w>
a therosclero
a re
W ar
Treat ment</w>
T -
PG -
P R
N S
L i
I D
D uring</w>
A t</w>
A S
( O
( H
( E
youn g</w>
wi de
v om
vom it
us ually</w>
um -
tu mor
tion s,</w>
thrombo sis</w>
throm b
th yro
te red</w>
t y</w>
sur viv
sup press
sup ple
secre tion</w>
s k
res h
requ ir
rel ative</w>
reco gn
recei ve</w>
re bell
rati o</w>
qu in
pro sp
prevent ed</w>
prev ent</w>
pit e</w>
physi ological</w>
per sist
pen ia</w>
pa in.</w>
on ucle
ol der</w>
ol ar</w>
o ti
o perative</w>
nitro glycer
n ine</w>
musc le</w>
moder ate</w>
migra ine</w>
metast atic</w>
manif est
man y</w>
mag ne
le s</w>
l ed</w>
iz ed,</w>
int ensity</w>
in suffici
ill ary</w>
i ally</w>
hyperten sion.</w>
hippocamp al</w>
h ic
gran ulo
gra de</w>
gly co
f entan
ext ent</w>
effect .</w>
e de
dyskine sia</w>
disor der</w>
correl ation</w>
convul s
contr ast</w>
cont ri
con sec
compar ison</w>
clear ance</w>
cholester ol</w>
ch o
ch loro
ch all
cardi om
carcin oma</w>
cal e</w>
brady cardia</w>
az ine</w>
ation s,</w>
appea red</w>
ane ously</w>
and ,</w>
an alo
aminoph en</w>
am il
aff ect</w>
adriam ycin</w>
ad ult
activ ity.</w>
abnormal ities</w>
a im</w>
U /
The refore,</w>
Th ir
S t
S P
N -
H g
FK50 6</w>
AT P
A s</w>
A )</w>
5- H
4 %</w>
3 0
2 00</w>
1 %</w>
) -induced</w>
yl line</w>
y r
week s.</w>
urac il</w>
upt ake</w>
to con
ti vi
th resh
te x</w>
t ure</w>
t al</w>
syndro me.</w>
sub c
strat es</w>
sel ected</w>
scor e</w>
resist ant</w>
res t</w>
regi men</w>
ref le
r y</w>
r as
r are</w>
prot ection</w>
pro per
po pul
platele t</w>
perio d.</w>
pec ially</w>
par ame
oxid ative</w>
outcom e</w>
ner v
ne on
maxim um</w>
mat ory</w>
mark ed</w>
lear ning</w>
k .</w>
intra ven
inf ected</w>
ind ing</w>
inc e</w>
impro ve</w>
immunosup pressive</w>
id o
i es</w>
hyperalge sia</w>
hist ory</w>
h orm
gent am
g all
fib ro
f usion</w>
ex hib
et amine</w>
est abl
es pecially</w>
elev ation</w>
dop aminergic</w>
do pa
dist urb
discontinu ation</w>
cys ti
cor tex</w>
contrast ,</w>
contrac ep
consec utive</w>
concl ude</w>
con duc
complete ly</w>
comp oun
co ag
ce rebell
cat al
b or
b ility</w>
at tac
at ed,</w>
an th
amphetam ine-induced</w>
am iodar
all ergic</w>
alco hol</w>
al ized</w>
al apri
addi tion,</w>
acet aminophen</w>
a ud
a em
T M
P O
Ne uro
N O</w>
N MD
I S
F or</w>
F i
D NA</w>
B ecause</w>
B P</w>
7 %</w>
3 )</w>
3 %</w>
20 0
19 9
1 9</w>
0.05 ).</w>
(n =
( M
( 7
y )</w>
wo uld</w>
vi rus</w>
ve hic
v es
um .</w>
ul ative</w>
u ter
u sion,</w>
transplant ation</w>
thromb ocyto
th ase</w>
test osterone</w>
tempor al</w>
syn thase</w>
sus cep
suscep ti
subsequ ent</w>
st ron
st rate</w>
st as
sex ual</w>
s in
s ).</w>
requ ired</w>
repor ted.</w>
recur rent</w>
re x
r o</w>
r in
r he
pyri dam
protein ur
protein s</w>
proce d
pro pi
pro phyl
pro ble
prim ary</w>
previ ous</w>
pressu re,</w>
post -
plic ation</w>
pl ac
pa thetic</w>
over all</w>
or tic</w>
or th
or der</w>
or ation</w>
om ic</w>
oly sis</w>
occur rence</w>
oc ript
ob j
not ed</w>
nitro prus
neuron al</w>
ne w
ne ed
mal i
li po
lead ing</w>
le .</w>
las tic</w>
l ast
l a
l ,</w>
it ory</w>
interv al</w>
ine ster
identi fied</w>
ic e</w>
hypoten sive</w>
hypo thesis</w>
he ad</w>
h al
group ,</w>
gre en</w>
g il
ex er
ex encephal
ex amine</w>
evalu ation</w>
eth yl
est radi
er gen
ent .</w>
em ergen
dynam ic</w>
dox orub
discus sed.</w>
diagnos ed</w>
dia bet
di pyridam
di c</w>
def in
de ath
d- type</w>
continu ous</w>
consist ent</w>
comp on
clon id
ci pi
character ized</w>
catal ep
caffe ine</w>
c al</w>
b one</w>
az epam</w>
av ail
ation al</w>
at in,</w>
as part
anti -
anc y</w>
al s.</w>
al -
adv anced</w>
administr ation.</w>
ab normal</w>
a ro
Whe n</w>
Th ree</w>
SR L</w>
S ub
S E
R es
R D</w>
P er
NMD A</w>
G A
E x
E n
Clin ical</w>
B B
Ac ute</w>
8 %</w>
5-H T
2 %</w>
1 8</w>
1 5
0 ,</w>
- related</w>
- like</w>
- associated</w>
) )</w>
( R
( -1
y ing</w>
xameth oni
wil l</w>
wide ly</w>
w a
vit ro</w>
vi a</w>
ven tion</w>
valu e</w>
use ful</w>
trem or</w>
treat ments</w>
trans por
toler ated</w>
tocon azole</w>
thresh old</w>
th io
t ex
t arg
sympto m</w>
subst anti
stri atal</w>
sti ll</w>
st age</w>
spont aneous</w>
sev of
sevof lur
seroton in</w>
seizures .</w>
se par
scopol amine</w>
s ci
s .
ro ph
rib avi
retur ned</w>
result ing</w>
reg ulation</w>
recomm en
re stric
rat ing</w>
random ly</w>
r ing</w>
r al
psych i
progres sion</w>
prob ably</w>
pro po
pro duction</w>
pilocar p
pi ri
patient 's</w>
path ological</w>
p. o
p as
ox ide</w>
or rh
oph ren
on ce</w>
ol .</w>
occur s</w>
nephro pathy</w>
my o
mus cular</w>
monit or
mon th</w>
mo od</w>
microgram s/
mg/kg ,</w>
meas ure
me g
man ag
m u
m ar
lo p</w>
las t</w>
labor atory</w>
k s</w>
iz ophren
is ed</w>
invol vement</w>
injec tion.</w>
inflam matory</w>
inf orm
in test
id ate</w>
ic ul
hypoten sion.</w>
hydrox y
hepat otoxicity</w>
hemo globin</w>
haem orrh
graph y</w>
foc al</w>
fact or
ev ere</w>
est ro
encephalo pathy</w>
enc es</w>
en alapri
e -induced</w>
drug s.</w>
di et
deve lop</w>
desi pramine</w>
de xameth
de signed</w>
d n
cum ulative</w>
cor tex
convul sive</w>
conver ting</w>
cont ent</w>
con si
co h
cloz apine</w>
clin ically</w>
cimetid ine</w>
cess ation</w>
ce f
ca the
c y</w>
c ent
bu tion</w>
biop sy</w>
bet a</w>
be tic</w>
bar ri
b ri
b inding</w>
atri pt
as pi
as es</w>
anti psycho
ant in
anc es</w>
al tern
agon ist</w>
adren aline</w>
ad ult</w>
acet ylcholine</w>
ac h
W h
U R
S evere</w>
S er
PG- 9</w>
P D</w>
M )</w>
ION :</w>
E Na
CI ,</w>
C )</w>
AN D</w>
AC E</w>
50 %</w>
0 00</w>
(2 )</w>
( mean</w>
( G
y st
we ll
w ent</w>
vol un
volun te
vas o
vas cul
ur g
un chang
um at
ult ra
ul ated</w>
ul arly</w>
u los
toxic ity,</w>
ti l</w>
tak en</w>
syn thesis</w>
suscepti bility</w>
sus p
surviv al</w>
sul ph
subc utaneous</w>
su per
stres s</w>
stra ins</w>
sto pp
st -
sp as
se ly</w>
sco res</w>
sch izophren
s oci
ro w</w>
ri z
rhe umat
re li
re cipi
re al</w>
random ized,</w>
ram idal</w>
ra pid
rapid ly</w>
ra b
r g
py ramidal</w>
psychi atric</w>
pro ces
pre dn
potenti ally</w>
po int
po in
perc ent
percent age</w>
per oxid
pen icill
p ose</w>
p -
ox ic</w>
ot rex
observ ations</w>
o pi
neuron s</w>
nephro tic</w>
morph ine-induced</w>
monit o
mo ve
mo di
min ute</w>
mil d</w>
micro sco
micro g/
mg/m 2</w>
meg al
medic ation</w>
main ly</w>
m ycin</w>
m l</w>
low ing</w>
lim it
level s.</w>
l ac
l .</w>
kg -1</w>
k al
j unc
iz e</w>
iti s</w>
it ation</w>
isoproteren ol-induced</w>
io p
inter val
inter action</w>
injec tions</w>
infarc tion.</w>
inester ase</w>
individ u
in toxic
impro vement</w>
i.v .</w>
hospit al</w>
hist or
h our</w>
gast ric</w>
gamma -
g k
ful ly</w>
fail ed</w>
f ts</w>
f en
ex ce
es s,</w>
episo des</w>
en ci
en .</w>
ec stas
e ph
e f</w>
diseas e,</w>
discontinu ed</w>
dialy sis</w>
dia betic</w>
di stri
demon strate</w>
decreas es</w>
de pression</w>
cyclophosph amide</w>
contracep tiv
consist ed</w>
conf idence</w>
concl uded</w>
coca ine-
chlor ide</w>
child ren
chem ist
character is
ch est</w>
cardiom yo
cardia .</w>
cap sa
brom ocript
bil ateral</w>
b ile</w>
aud itory</w>
as ym
are a</w>
anti bio
anim al</w>
an em
ami l</w>
al k
ak athi
adriam yc
achi eved</w>
ac tic</w>
ac t</w>
ab ine</w>
a reas</w>
a ortic</w>
] o</w>
Z D
Tw ent
T .</w>
S im
N T
N P</w>
L )</w>
I )</w>
H y
Fi ve</w>
Eff ect</w>
E )</w>
D 3</w>
C S
C PA
B oth</w>
B as
9 -
8 0</w>
8 -
5- F
4 00</w>
3 .</w>
2. 5</w>
2 ).</w>
2 %)</w>
10 0
1 6
1 3.
0.05 )</w>
0.00 1).</w>
0. 7
( L
( 95%</w>
( 1</w>
year s.</w>
y cl
y ).</w>
xim ately</w>
week s,</w>
war farin</w>
w all</w>
v inc
v es</w>
us al</w>
ure tic</w>
under went</w>
under go
ulos clero
ul es</w>
uc h</w>
tivi ties</w>
ti tive</w>
the re
th ym
th ia
ten ded</w>
te en</w>
t le</w>
t ain</w>
symptom s.</w>
suppor t</w>
supple ment
subj ect
sub un
su peri
sit es</w>
sit e</w>
sim vastatin</w>
sh e</w>
sensi tiz
se em
s gk
sgk 1
ro ut
riz atript
ribavi rin</w>
ret ro
ret inal</w>
resol ved</w>
ren atal</w>
remain ing</w>
regar ding</w>
recur rence</w>
recor d
receptor s.</w>
reas t</w>
re plac
rat es</w>
rat e.</w>
ran s
radi o
qu es
propo f
propof ol</w>
pro cess
prev al
pol ys
po ster
pheny le
pharmac ological</w>
perform ance</w>
patient ,</w>
pat tern
paclitax el</w>
pa in,</w>
p se
p on
oxy gen</w>
oxif ene</w>
on avi
on ate</w>
ol us</w>
ol i
o pa
nucle us</w>
neuro pathy.</w>
necro sis</w>
n i
n al</w>
mor t
monito red</w>
mod ul
mit ted</w>
microangio pathy</w>
micro g
mic e,</w>
mg/k g/
me tri
mas sive</w>
mali gn
mag nit
m ,</w>
lun g</w>
loc ated</w>
lo z
literat ure</w>
li pid</w>
le sto
lat ency</w>
k g</w>
ist s</w>
is h</w>
intraven ously</w>
intest inal</w>
int ram
int en
insuffici ency</w>
ine ur
induc es</w>
indic ated</w>
in- treated</w>
in do
in dependent</w>
horm one</w>
high ly</w>
hepati tis.</w>
headac he</w>
gram s</w>
glomer ulosclero
gentam icin</w>
gener alized</w>
g um</w>
g ree</w>
g ab
func tion.</w>
fron tal</w>
fibrill ation</w>
fi el
fe w</w>
f y</w>
f iltration</w>
f atal</w>
ex cl
ent ,</w>
en d
elder ly</w>
e pt
e ight</w>
dysfunc tion.</w>
du al</w>
doc um
det ected</w>
del ayed</w>
de x
de pres
de li
de gree</w>
de d.</w>
da ys
da y,</w>
d o</w>
d ensity</w>
cor tis
cor respon
convuls ant</w>
conver sion</w>
conduc ted</w>
con sequ
con sci
common ly</w>
ch arg
but ed</w>
bupivac aine</w>
bo di
block ed</w>
block ade</w>
behavi or</w>
bas al</w>
b reast</w>
b olus</w>
b i
b ec
aw are</w>
ati c
as al
appro ximately</w>
antidepress ant</w>
ance ment</w>
ance .</w>
amoun t</w>
am ne
al ter
al ce
ad ine</w>
act ing</w>
acet am
a ut
a udi
a im
T H
S SR
P T
O n</w>
O R</w>
N one</w>
N S</w>
N R
MR P
L- arginine</w>
Im mun
H g</w>
G ra
G N
F urther</w>
F ol
ES RD</w>
C NS</w>
C I</w>
B D
An ti
ATP ase</w>
7 0</w>
5- fluoro
5 )</w>
4 8</w>
4 0
3 2</w>
2 3</w>
2 .</w>
/ -
(1 5</w>
( 9
wil d-type</w>
wh ere</w>
well -
w ay</w>
vi ous</w>
verap amil</w>
uro mycin</w>
un til</w>
ult ras
tre oti
transplant ation.</w>
tic s.</w>
tic lop
thrombo emb
thir d</w>
ten s
t a</w>
sym pathetic</w>
superi or</w>
sulf ate</w>
strok e</w>
smo king</w>
sion -
side -
si g
sens or
se ve
sch ed
sam ple
s. c
s ing</w>
s c
rit onavi
rig idity</w>
rib ute</w>
res c
reduc ing</w>
recor ded</w>
reco vered</w>
re ten
re si
re se
re p
rang e,</w>
quanti t
pu bl
prophyl actic</w>
prop yl
pro li
proli fer
prevent ing</w>
pra gu
pragu e-
prague- D
prague-D aw
prague-Daw le
prague-Dawle y</w>
poster ior</w>
possib ly</w>
po p
plas tic</w>
plas mic</w>
physi cal</w>
pen s
patho genesis</w>
par acetam
pap aver
p lo
p ep
ot yp
ot er
os f
org an
or ally</w>
onucle o
on omic</w>
on al</w>
ocy an
obser ved.</w>
obj ective</w>
o t</w>
o per
o ff
o d.</w>
nitroglycer in</w>
nerv ous</w>
necess ary</w>
ne ut
n g/
month s,</w>
mol ec
mol /
ml /
minist ration</w>
microgram s</w>
mi x
mg/d L</w>
methyl phen
meth otrex
ment s.</w>
mat ch
mark ers</w>
mark er</w>
mar row</w>
ma z
ma in</w>
m al</w>
los s.</w>
lo x
li g
levo dopa</w>
le ast</w>
le ad</w>
le -
ke toconazole</w>
is ,</w>
ip olar</w>
int ake</w>
infu sions</w>
immun e</w>
i.p. )</w>
hyper kal
hepat oc
hemorrh agic</w>
he x
gra v
gra m</w>
gener al</w>
gall bladder</w>
fic ial</w>
fac ial</w>
f l
exten sive</w>
exhib ited</w>
erg ot
equ al</w>
eph ed
enh ancement</w>
enalapri l</w>
ect om
dyskine si
dose- dependent</w>
disorder s.</w>
diff er</w>
deter i
depress ed</w>
defici ency</w>
de part
de m
d on
cysti tis</w>
cyclophosph amide
creat ine</w>
cour ses</w>
cor ding</w>
cont ribute</w>
condi tions</w>
concl usion,</w>
comp an
coll ag
cerebell ar</w>
cell s.</w>
cTn T</w>
c ult
block ers</w>
bloc k</w>
biop si
bil i
b um
b it
b ipolar</w>
b ing</w>
aut onomic</w>
attenu ated</w>
at tri
at er
at e.</w>
at e-
aspart ate</w>
ari ly</w>
ar rest</w>
appear s</w>
analo gu
an xi
amph oter
amiodar one</w>
amin onucleo
al tered</w>
al le
al bum
aim ed</w>
activ ity,</w>
ac ro
ac compan
a ph
] -
U sing</w>
Th us,</w>
S prague-Dawley</w>
S E</w>
P D
P ,</w>
Na +
N F
L ,</w>
E 1</w>
DO X</w>
C o
C ardi
C ap
C R</w>
B e
B /
Ad ministration</w>
< 0.0
8 ),</w>
7. 5</w>
6 )</w>
3 6</w>
2 7</w>
2 4
2 2</w>
19 8
, 000</w>
( 3.
% ;</w>
wh ite</w>
we ak
viv o</w>
ven tional</w>
us ual</w>
ur ther
ur rent</w>
undergo ing</w>
ul c
typ ical</w>
tre at</w>
toler ance</w>
to pri
to p
to co
ti mo
the m</w>
th ,</w>
tac rolim
syn ap
sup pres
suc cess
star ted</w>
st re
st ained</w>
st able</w>
spont aneously</w>
sion s.</w>
sign al
sh ort</w>
sevoflur ane</w>
sal t-
s he
s al</w>
ro x
ro l
rizatript an</w>
rit er
ris perid
rheumat oid</w>
revie w</w>
resist ance</w>
res on
reson ance</w>
requir e</w>
reg ul
refle x</w>
recogn ized</w>
rec ently</w>
re ly</w>
r ical</w>
r ic
pur pose</w>
pto m
prov ide</w>
propi on</w>
prof ile</w>
pro st
preval ence</w>
predn isol
pre vention</w>
pre treated</w>
pre mat
pre domin
praz ol
pot ent</w>
pot assi
possib ility</w>
pos ed</w>
pilocarp ine-induced</w>
ph r
per me
per it
partic ularly</w>
parame ters</w>
par k
park inson
p ut
p uromycin</w>
p s</w>
p al
p H</w>
over dose</w>
ot ro
ot rans
os ine</w>
org an</w>
ore o
or por
op en</w>
on e-
occur red.</w>
occ ur</w>
oc ular</w>
oc ept
o d-
nor adrenaline</w>
nicot ine-induced</w>
nec k</w>
n oc
my e
mus car
mu co
mort ality</w>
morph ological</w>
monitor ing</w>
mon ke
molec ular</w>
model .</w>
mo re,</w>
mm Hg
methyl -
meth amphetamine</w>
men opa
maxim al</w>
match ed</w>
manag ement</w>
magne tic</w>
m ed</w>
lu co
long er</w>
lon g</w>
lo be</w>
lo ad
lim ited</w>
li gh
lesto lol</w>
le p
le ar</w>
lat er</w>
las ma</w>
lamivud ine</w>
l act
k g/
k etamine</w>
isoproteren ol</w>
isol ated</w>
is ing</w>
insti ll
initi ation</w>
inf ection</w>
in s.</w>
in oma</w>
in contin
immedi ate</w>
if osf
ide ,</w>
id om
ic in-induced</w>
ic ardi
i onic</w>
hy d
h all
graph ic</w>
gene tic</w>
gen ous</w>
g/ d
g em
fol d</w>
fiel d</w>
f lur
f ed</w>
extra pyramidal</w>
ex cre
estim ated</w>
erythro cy
ergot amine
ergotamine /
epilep tic
ephed rine</w>
ent ly,</w>
enci es</w>
emergen cy</w>
el ic
ede ma</w>
ed ly</w>
duc t</w>
dog s</w>
docum ent
dis ru
di ed</w>
di azepam</w>
dexameth asone</w>
det ection</w>
descri bed</w>
descri be
defic its</w>
def ect
day s,</w>
dam age.</w>
cyclospor ine</w>
cros s-
cortex .</w>
consum ption</w>
compoun ds</w>
com pl
co w
car ri
cap illary</w>
ca ref
c riter
block ing</w>
behavi or
barri er</w>
b ur
avail able</w>
atro pine</w>
at tem
at s</w>
appe ti
appe ar</w>
anti gen</w>
anti epileptic</w>
antagonist s</w>
ant s.</w>
am ine.</w>
am ant
alpha- methyl
allogra ft</w>
adjust ment</w>
activ ation.</w>
accum ben
accompan ied</w>
ac u
ac coun
ac cording</w>
a si
War farin</w>
W e
V )</w>
The y</w>
TA M</w>
S he</w>
S e
R en
R )</w>
P lasma</w>
P g
P ain</w>
GA BA
G )</w>
ENa C</w>
D ES
Ca Cl
C D
B y</w>
A R
A ,</w>
9 9
8 ).</w>
50 -
5-fluoro uracil</w>
3 5</w>
3 0-
2 ,
10 (-
1 5-
0. 1</w>
, 4-
(1 .
( AC
( 50</w>
( 10
z e
ze tim
zetim i
year .</w>
yc lo
y :</w>
xamethoni um</w>
war far
w id
vol u
ves sel
ven l
venl af
venlaf ax
vari abl
urther more,</w>
up per</w>
ul l
trans fer
tra in
to in</w>
to ge
ti d</w>
ti ally</w>
thromboemb ol
thrombocyto penia</w>
thia sis</w>
the oph
t or
t oly
t as
syn erg
surger y.</w>
suff ering</w>
sub sti
sub arac
subarac h
subarach no
subarachno id</w>
sub -
stron g</w>
striat um</w>
strat e
ston es</w>
steroid s</w>
ster oid</w>
sp ac
sk in</w>
side -induced</w>
si x
sens ory</w>
seizures ,</w>
se mi
sched ul
sample s</w>
sal t</w>
saf e</w>
s om
s es
s cre
s '</w>
ron id
ri st
reten tion</w>
respectivel y).</w>
res .</w>
rel ap
reg ular</w>
ref l
reac tive</w>
re tic
ran o
ral oxifene</w>
quin ol
pyri dox
publ ished</w>
prop rano
pro por
pro ca
pregn an
pre ad</w>
potassi um</w>
pop ulation</w>
poin t</w>
pl ays</w>
phosph ate</w>
pheny toin</w>
ph thal
pep ti
paracetam ol</w>
par aly
p t</w>
ox et
otro pic</w>
otrans fer
otoxic ity.</w>
oreo ver,</w>
one ph
om as</w>
ol /
occur ring</w>
oc treoti
oc cl
o vari
o ther
no v
no rep
nitroprus side</w>
neuro tens
neuro lep
neg ati
need ed</w>
ne um
n or</w>
n .</w>
mye lo
move ments</w>
mod ulation</w>
min or</w>
min .</w>
mg )</w>
metri c</w>
methylphen idate</w>
met ronid
menopa usal</w>
medic ations</w>
mat ri
magnit ude</w>
m s.</w>
m M</w>
loz enge</w>
lox ac
lo cal
lo ca
loca ine</w>
lit tle</w>
lif e</w>
le gil
larg e</w>
la be
l amin
kidne ys</w>
k e</w>
is e</w>
ir th</w>
intram us
intra renal</w>
interv als</w>
int ro
inhib it</w>
ing s.</w>
ing es
inf er
inf ec
ine- treated</w>
indic ates</w>
inc orpor
implic ated</w>
id ural</w>
id en
hyperten sion,</w>
halo th
group s,</w>
go od</w>
glomerul oneph
gest ation</w>
g luco
g in
g all</w>
fol inic</w>
find ing</w>
f -
experim ent
experi ence</w>
ex ist
ev ent</w>
estradi ol</w>
es cap
er s,</w>
episo de</w>
ep inephrine</w>
ep idural</w>
endo genous</w>
em o
electro cardio
ect ing</w>
e y
e )</w>
dopa -induced</w>
do but
distri bution</w>
disorder s</w>
dipyridam ol
differen tial</w>
diagnos tic</w>
diabet es</w>
di min
der i
demon strates</w>
defici ent</w>
d one</w>
cor tical</w>
control s,</w>
control .</w>
continu ed</w>
consi der
con sti
con i
compon ent</w>
coh ort</w>
clo se</w>
cl assi
cl as
cin ac
cinac alce
chemo therapy.</w>
characteris tics</w>
ch rom
cer tain</w>
cau tion</w>
can n
c li
c ed</w>
bupivac a
bromocript ine</w>
brady kin
bodi es</w>
blo od-
bio chemical</w>
bene ficial</w>
bas ement</w>
bac ter
b asis</w>
b al</w>
avoid ance</w>
attac k</w>
at yp
as ,</w>
arter i
arrhyth mi
arc h</w>
ar m</w>
appeti te</w>
appa rent</w>
apo morphine-induced</w>
anti bodies</w>
ant s,</w>
ant ly</w>
ance ,</w>
analy zed</w>
anaesthe sia</w>
amphoter icin</w>
amin otransfer
am pl
album in</w>
akathi sia</w>
ag gres
ag e
adren ocept
adjust ed</w>
ade qu
addi tional</w>
acro megal
ab o
ab domin
a ort
a k</w>
a c</w>
V P
U n
U -
Twent y-
S cale</w>
S E:</w>
S C
Ren al</w>
R g
Ph armac
Pg p</w>
NR A
NRA 0
MRP 2</w>
METHOD :</w>
M oreover,</w>
M e
M al
L EP
LEP P
L B/
K -
H D
Gra de</w>
Fol lowing</w>
F urthermore,</w>
F K</w>
F )</w>
Eff ects</w>
E P</w>
E D</w>
D ru
D es
C ont
C H
C E</w>
C C
C A</w>
BA LB/
A m
A g
9 ,</w>
8 )</w>
7 5</w>
7 )</w>
5-F U</w>
4 6
4 ,</w>
34 4</w>
3 6
20 -
2 50</w>
2 ),</w>
1. 0</w>
0 %)</w>
/ ml
( range</w>
( I
( +/-
year s,</w>
y et</w>
wor k</w>
wh ose</w>
weigh t,</w>
w at
vomit ing,</w>
vinc rist
vehic le</w>
ve -
vascul itis</w>
vac u
us h
ur ia,</w>
und red</w>
um ar
um -induced</w>
ultras ound</w>
ul f
uc in
typ es</w>
tw ice</w>
tub ular</w>
toxic ities</w>
top ical</w>
to po
to -
ti me,</w>
ti le</w>
thyro id</w>
th us</w>
th .</w>
test ing</w>
te tra
te in
targ et
tachy cardia.</w>
t ut
t ur
t s.</w>
t in
t able</w>
t able
t AM
surger y</w>
ste re
star ting</w>
sp ective</w>
smo k
show s</w>
sh or
separ ate</w>
sec ret
secret ory</w>
se legil
s pi
s over</w>
s ince</w>
s cal
s ar
ru ising</w>
ros s</w>
ro lled</w>
revie w
respon sible</w>
remain s</w>
rele as
rel atively</w>
ref er
reduc es</w>
recommen ded</w>
rec t</w>
re verse</w>
qu e</w>
proper ties</w>
pro vid
pro m
pro fi
pro cess</w>
prim arily</w>
pri ate</w>
prescri bed</w>
pres ents</w>
pregn anc
prednisol one</w>
pre g
preg ulation</w>
polys ac
polysac ch
po or</w>
po d
placebo -
phenyle phrine</w>
phenobarbit one</w>
pharmac o
perit one
patient s)</w>
partic ular</w>
papaver ine</w>
pac t</w>
p- co
p-co umar
p unc
p ron
p renatal</w>
p rac
p .</w>
oxid ant</w>
ox amine</w>
out co
or ity</w>
oph il
one -induced</w>
on in</w>
ol one</w>
ocyan ine</w>
oc ca
o plastic</w>
o ,</w>
nicot inic</w>
neurolog ic</w>
neuro muscular</w>
nause a,</w>
n g
n atri
natri uretic</w>
myo pathy</w>
muscar inic</w>
mus t</w>
mon o
mon g</w>
mo vement</w>
mix ed</w>
mg/ day</w>
mg .</w>
methotrex ate</w>
meth amphetamine-induced</w>
ment ,</w>
medi a</w>
med ull
meas ure</w>
mat o
mark edly</w>
malign ant</w>
maint ained</w>
m ia.</w>
log y</w>
log ical</w>
literat ure.</w>
lin es</w>
lig and
li ght</w>
level .</w>
leuk emia</w>
le t
lat ter</w>
lat er.</w>
las er</w>
lamin a</w>
l ic
l -
k appa
k -
j ects</w>
is ch
intrac erebral</w>
intra peritone
initi ated</w>
infu sion.</w>
inform ation</w>
ind ocyanine</w>
inc id
in st
in de
in ally,</w>
import ance</w>
implic ations</w>
immuno histo
immedi ately</w>
im odi
if ost
idom ide</w>
ici ans</w>
i an</w>
hypoten sion,</w>
hyperkal emia</w>
hist ological</w>
hist amine</w>
high est</w>
hepatoc ellular</w>
hemat oma</w>
h undred</w>
h n
h ab
h ,</w>
granulo mato
glo bul
gl uc
gener ally</w>
gener 's</w>
gen e</w>
gamma -H
g s</w>
g er</w>
g a
fo ot</w>
flu oxet
fic ation</w>
fibro sis</w>
ffe red</w>
fer ri
fail ure,</w>
fac il
f et
f av
expl or
experim ents</w>
exencephal ic</w>
ex cit
ev id
est er
escap e</w>
es tive</w>
epile psy
enh ance</w>
enc y,</w>
en apine</w>
electro n</w>
ed ing</w>
ecstas y</w>
ech ol
ear li
e rec
dos es,</w>
do w
dis charg
di ast
diast olic</w>
di ame
develop mental</w>
des pite</w>
deple tion</w>
defin ed</w>
defic it
de oxy
da y.</w>
d ent
d en
criter ia</w>
confir med</w>
compar able</w>
com pens
coag ulation</w>
co ch
clo sely</w>
chron ically</w>
cholest asis</w>
chall enge</w>
chall eng
ch ic
catalep sy</w>
carcino ma.</w>
canc er.</w>
calc ineur
c ranial</w>
blood- brain</w>
beta- adrenergic</w>
beta 4</w>
behavi ors</w>
b ruising</w>
b re
b irth</w>
b an</w>
auto ph
audi o
atten tion</w>
ation -
at or</w>
asym ptom
ast ro
ast er
ass ay</w>
aspi rin</w>
as signed</w>
as enapine</w>
as c
arth ri
ar t
ar ly,</w>
appro priate</w>
appear ance</w>
antin ociceptive</w>
angio genesis</w>
aneurys m</w>
and ro
analge sic</w>
an ionic</w>
ame li
amant adine</w>
am ine,</w>
am ic</w>
al ox
agon ist
aem ic</w>
ad mitted</w>
acet yl
accumben s</w>
ac ce
abs or
abnormal iti
abil ity,</w>
abdomin al</w>
Y 27
Y27 46
X -
Wh ile</w>
We gener's</w>
W S
W R
UR PO
URPO SE:</w>
U/ L</w>
TR (-
Sub jects</w>
S uch</w>
S /
S .</w>
R ats</w>
Q T</w>
Pre vious</w>
PR L</w>
PA N
P o
P URPOSE:</w>
P <
N G
Me an</w>
MP -
M R</w>
M MP-
M C
M -
M ),</w>
LEPP 1</w>
L Y2746
In trac
In c
H ist
H b</w>
H A
H -
GF R</w>
G SP
G LEPP1</w>
F inally,</w>
F AN
E V
E S:</w>
E NT
E G</w>
E 1
Des pite</w>
Com par
C oc
C G
B ZD
B W
B S
B .</w>
AL F</w>
A s
A rab
A mong</w>
A I
8 00</w>
7 8</w>
7 ).</w>
6 2</w>
5- year-old</w>
5 00</w>
5 .</w>
5 %)</w>
4 4</w>
4 2</w>
4 0-
10 %</w>
1. 5</w>
1 60</w>
1 20</w>
1 ,
0 0
/- )</w>
- free</w>
+ )</w>
(A OR</w>
(2 )-
(+/- )-
( r</w>
( Na
( N</w>
( HB
( 5</w>
( 3</w>
wor sen
wom en.</w>
wit ch</w>
wid es
wides pread</w>
wh ole</w>
wat er</w>
war d</w>
w ays</w>
volunte ers</w>
vi ron
verap amil
venlafax ine</w>
ven til
vast at
vari able
variable s</w>
v s</w>
v oid</w>
v ation</w>
use ,</w>
us ers.</w>
ur able</w>
un usual</w>
un treated</w>
un t</w>
un dic
ult s</w>
ul fi
ucin ations</w>
u do
tri al.</w>
tr ic
toly l</w>
to pro
tiz ed</w>
throu gh
through out</w>
throm bin</w>
ther mia</w>
test .</w>
ter n</w>
ter min
ter but
terbut aline</w>
tacrolim us
t ting</w>
t ory</w>
t onic</w>
t ech
system .</w>
susp ected</w>
sur fac
surfac e</w>
sup pression</w>
suffici ent</w>
substanti al</w>
subj ective</w>
su stained</w>
studi ed.</w>
stre pto
spas m</w>
sol ution</w>
sm all
signal ing</w>
si a,</w>
seri es</w>
seiz ure
secon ds</w>
s qu
s par
s cale</w>
rout ine</w>
ro un
ritonavi r</w>
ri se</w>
retur n</w>
restric ted</w>
resol ution</w>
resi dual</w>
requ i
repe ated
repeated ly</w>
ren tly</w>
ren e</w>
rel ax
regimen s</w>
regimen .</w>
regi ons</w>
reg urg
ref rac
refrac tory</w>
record ings</w>
reco ver
rec ent</w>
re mission</w>
re lev
ra z
ra g
r y
r l</w>
r ho
r e</w>
r TM
ques tion
quantit ative</w>
qu ality</w>
pul se</w>
pse ud
provid ed</w>
proteinur ia.</w>
prot ect</w>
prosp ectively</w>
propor tion</w>
pron oun
pronoun ced</w>
pro toco
pro state</w>
pri locaine</w>
present ing</w>
pregn ant</w>
pre term</w>
pre par
pre dis
praz os
post menopausal</w>
polysacch ar
polysacchar ide</w>
poly morph
placebo ,</w>
pl ied</w>
pl ay</w>
pl atin</w>
pharmac ologic</w>
pha sic</w>
ph a</w>
persist ent</w>
peroxid ation</w>
per icardi
per g
perg ol
pe th
patient .</w>
path oph
pathoph ysi
pat tern</w>
particip ants</w>
parkinson ian</w>
par t</w>
par a
pac em
pacem ak
pa ren
p anic</w>
over dose.</w>
ovari ectom
ovariectom ized</w>
ous ly.</w>
oun d.</w>
ot oc
ost atic</w>
os in
osin ophil
org anic</w>
on g
on 's</w>
odi lat
oc arc
observ ation</w>
ob struc
ob lastic</w>
nov o</w>
normal .</w>
nit ric</w>
nit ed</w>
ng .
ng. /ml
neuro trans
neuro toxicity.</w>
neuro pathic</w>
nephro toxicity</w>
nephro toxic</w>
ne x
n s</w>
n ess,</w>
myocardi tis</w>
monke ys</w>
minut es.</w>
microgram /
microg lial</w>
mi pramine</w>
meth od</w>
metabol ism</w>
met ab
medi ate</w>
me topro
mac roph
ma ,</w>
m L</w>
los art
locom o
loc al</w>
lo l
lipo ic</w>
ligand s</w>
lidoc a
li gi
level s,</w>
le thal
le sion</w>
le d
lat er,</w>
last ing</w>
lamivud ine-
l ing</w>
know led
iti s,</w>
it onin</w>
it h</w>
it ary</w>
ish ing</w>
ischem ic</w>
intrac ranial</w>
intrac or
interval ,</w>
interac tions</w>
insti tu
inhib i
inges tion</w>
ine phr
induc ing</w>
indo l</w>
individ ual</w>
incontin ence</w>
includ e</w>
inc lu
in ity</w>
in a</w>
im pl
im pact</w>
il lu
if edi
identi fi
id ine-induced</w>
ic s</w>
i um</w>
i di
i ble</w>
i -
hypo x
hemat ologic</w>
haloth ane</w>
hal f</w>
haem oly
hab it
h r</w>
glomerulosclero sis</w>
gen ic
gab ap
g y
g e,</w>
find ings.</w>
fentan yl</w>
f ur
ex trem
ex p
evalu able</w>
ev er</w>
estro gen</w>
establ ished</w>
es sen
ergotamine/ caffeine</w>
epileptic us</w>
ence ment</w>
ence .</w>
en viron
en co
em plo
ect ro
ec al</w>
e- control</w>
e ve</w>
drug s,</w>
dow n
dos age</w>
dog s.</w>
doc rine</w>
divid ed</w>
det ect
depend ently</w>
def er
def ects</w>
de generation</w>
de ,</w>
da il
d- generation</w>
cum in</w>
cri tical</w>
cow s</w>
cortico sterone</w>
correspon ding</w>
cor d</w>
contraceptiv es</w>
con ventional</w>
con stric
comple tion</w>
comp ris
comm encement</w>
coll ected</w>
coca ine.</w>
cloz ap
cispl at
cholest atic</w>
chol ine-
children .</w>
chemist ry</w>
character istic</w>
ces sive</w>
cep t</w>
ce ph
cat echol
cas e-control</w>
cardiomyo pathy</w>
cardia ,</w>
cardi otoxicity</w>
cann ab
calcineur in</w>
calc itonin</w>
bu propion</w>
bri ef</w>
bradykin in</w>
ble eding</w>
bili ru
b ron
b ro
b ic
azep am
atro ban</w>
asymptom atic</w>
asal azine</w>
as .</w>
arth ritis</w>
arg atroban</w>
ap ne
anim als.</w>
anesthe sia</w>
an ol</w>
an .</w>
ampl it
amide ,</w>
ameth asone</w>
ameli or
am ine-induced</w>
am ifost
alter ations</w>
allogra fts</w>
al most</w>
af in
adult s</w>
adequ ate</w>
ad ded</w>
acu te
acid .</w>
acid ,</w>
acet ate</w>
abol ished</w>
abo ve</w>
a undic
a ir
Y P
War far
W ith</w>
V N
U- II</w>
U nited</w>
Thir ty-
TR(- )</w>
T est
S u
S ince</w>
S T
S NP</w>
S BP</w>
S ,</w>
Rg 1</w>
Pharmac o
NRA0 160</w>
N I
M y
M or
M A</w>
M ,</w>
L- dopa</w>
L ong
L o
L /
Immun o
IC H</w>
I s</w>
I T</w>
I L-
I -
Hy per
H igh
H er</w>
H e</w>
H IV</w>
Grou ps</w>
FAN F
F rom</w>
ES RD
EP O</w>
Di fferen
De x</w>
D o
CaCl (2)-
CR F</w>
C erebral</w>
C YP
C P
C B
C ,</w>
Bas ed</w>
BALB/ C</w>
B ra
Arab ic</w>
Ad riam
AD AM
A z
9 2
9 )</w>
8 ,</w>
7 2</w>
6 1</w>
6 .</w>
4 0%</w>
4 )</w>
4 ).</w>
3 7</w>
10 3
1. 9</w>
1 4.
1 2.
1 /
1 .</w>
0. 5</w>
/ 8),</w>
- I</w>
( i
( 8
( 2</w>
( 100</w>
ylchol inesterase</w>
yl )
weigh ted</w>
weak ness</w>
war ran
w er</w>
vomit ing</w>
ve in</w>
vast atin,</w>
vari ant</w>
valpro ic</w>
v oc
ure a</w>
urac il
ur ally</w>
up on</w>
up ancy</w>
up .</w>
up -
ultra structural</w>
ulc er</w>
u ti
u pregulation</w>
tumor s</w>
transpor t</w>
trans formation</w>
to b
tissu es</w>
timo lol</w>
tim al</w>
tic -
ti ve,</w>
ti es.</w>
ti az
thromboembol ism</w>
therap y-
theoph ylline</w>
thal idomide</w>
th ors</w>
th or
th en
th ecal</w>
test s,</w>
ter ior</w>
ter .</w>
tein uria</w>
tech ni
tAM CA</w>
t on
t ent</w>
t ardi
tardi ve</w>
t a
syndro me,</w>
synap tic</w>
syn the
switch ing</w>
surg ical</w>
suppor ts</w>
supplement ation</w>
success fully</w>
subject s.</w>
subj ected</w>
su d
studi es.</w>
studi es,</w>
stra in</w>
statis tical</w>
star t</w>
st ret
spec imen
sol u
so me
sle ep
sion s,</w>
sion al</w>
sing le-
simil ar
si z
si dic</w>
si c
si a
short -term</w>
short -
she ll</w>
sgk1 (
sgk1( +/
seve rely</w>
sequ el
sequel a
selegil ine</w>
seem s</w>
sed ation</w>
se em</w>
scre ening</w>
s/ RD
s.c .)</w>
s on</w>
rox ic
rou gh</w>
ron ol
ronol act
rom ol/
ro pi
ri um</w>
rever sib
retic ul
rese arch</w>
requir ing</w>
repor t.</w>
repe titive</w>
ren di
rel ation</w>
regurg itation</w>
regimen s.</w>
regi on
reg res
ref e
refe rence</w>
reduc tions</w>
recipi ents</w>
receptor .</w>
reac h
re sto
re plication</w>
re pa
repa ir</w>
re m
re j
rati o
rat e,</w>
ra re.</w>
punc t
pu t</w>
psycho sis</w>
pseud oli
prov o
prost ag
prostag l
prostagl and
prolifer ation</w>
produc ts</w>
produc t</w>
process es.</w>
proces ses</w>
proble m</w>
pro vi
present ed.</w>
prescri bing</w>
premat ure</w>
predic tive</w>
pre fer
pre ce
prac ti
port al</w>
pod ocyte</w>
po or
pi roxic
physi ci
phosph at
ph y</w>
peth idine</w>
perme ability</w>
per fusion</w>
per azine</w>
pepti de</w>
pen ile</w>
pe ak</w>
pattern s</w>
pathophysi ology</w>
path ology</w>
pas sive</w>
par tially</w>
paclitax el
pacemak er</w>
p ic
p e</w>
p all
oxy gen
out put</w>
ou s,</w>
ou ght</w>
ot al</w>
os sible</w>
os pas
os om
orth ostatic</w>
organ ization</w>
op ic</w>
oni az
ocy tes</w>
occl usion</w>
occ upancy</w>
oc lon
o v
o ro
o pen
norep inephrine</w>
non- selective</w>
nit rendi
ng./ml .</w>
nex t</w>
new bor
neut ro
neurotens in</w>
neuro toxic</w>
neuro protective</w>
neum on
n ociceptive</w>
n imodi
n ight</w>
n ifedi
n ative</w>
n at
n alox
n =
my olysis</w>
mut ations</w>
mul tic
mor b
mod afin
mo tility</w>
mit tent</w>
mis sion.</w>
mid d
microsco pic</w>
microsco p
mic romol/
mg/kg/ day</w>
mechan ical</w>
me ll
mell it
matri x</w>
mas s</w>
manifest ations</w>
man ic</w>
mal tolyl</w>
mal es</w>
maj ority</w>
magne si
ma ze</w>
mR N
m t
m ade</w>
m T
lymph oblastic</w>
low- dose</w>
low ering</w>
losart an</w>
lo od</w>
lithi um-induced</w>
limit ing</w>
ligi ble</w>
li throm
levo dopa-induced</w>
l ing
l ine
l d</w>
know n.</w>
kg )</w>
kappa B</w>
iz ing</w>
isol ated
isolated -H
is oniaz
is on
investig ations</w>
inv a
inva sive</w>
intra thecal</w>
inter mittent</w>
ino gen</w>
injur y.</w>
inhibitor s.</w>
inhibitor ,</w>
inhibit s</w>
infer ior</w>
inf requ
ine 's</w>
ind ol
ind ,</w>
increas ed,</w>
inc t</w>
in te
in si
in ol</w>
impl ant
il l</w>
ifosf amide</w>
identi fy</w>
ide .</w>
i ous</w>
hyper thermia</w>
hyper sensitivity</w>
hydro chloride</w>
ho mo
histo pathological</w>
hippocamp us</w>
high- risk</w>
hi al</w>
hepar in</w>
headac he
he l
haloperid ol-induced</w>
haloperid ol,</w>
hall ucinations</w>
h ol
h en
gra du
glomeruloneph ritis</w>
glo bin
gin ning</w>
gi ven
gast ro
func tion
frequ encies</w>
fo ur
fir st-
fem oral</w>
fe rence</w>
fe ed
f ut
f ound.</w>
f ind</w>
exencephal y</w>
excre tion</w>
ex pres
event s.</w>
evalu ated.</w>
et ax
etax el</w>
estim ate</w>
es s.</w>
es )</w>
erg y</w>
epilep sy</w>
en d-
em ,</w>
elect rical</w>
echocardiograph y</w>
echocardiograph ic</w>
ec it
e zetimi
e ti
e re
e NO
e :</w>
dyskinesi as</w>
drug ,</w>
doxorub icin</w>
dose ,</w>
dos es.</w>
doc etaxel</w>
dobut amine</w>
do myolysis</w>
disturb ance</w>
dist inct</w>
disru ption</w>
dis ulfi
direc tly</w>
dil tiaz
dil ated</w>
di z
determin ation</w>
deteri oration</w>
depart ment</w>
de void</w>
de pri
de n</w>
cyc les</w>
cy tot
cy cl
cros sover</w>
cortico steroid
contri but
consci ous</w>
coni ine</w>
confir m</w>
conf usion</w>
conf oun
condi tion</w>
con junc
con g
con cer
con cent
compar e</w>
collag en
cit abine</w>
cispl atin,</w>
cir cul
cinacalce t</w>
cho w</w>
cas es.</w>
carri ed</w>
carb on</w>
car bo
can not</w>
ca ro
cTn I</w>
c m</w>
bu min
bron ch
block ers.</w>
block er</w>
bl ind</w>
benz yl
aundic e</w>
au thors</w>
atic ally</w>
atherosclero tic</w>
atherosclero sis</w>
at or
at o
at a</w>
as e.</w>
arter io
arrhyth mic</w>
arrhyth mia</w>
ar y,</w>
appro ach</w>
apo pto
apo morphine</w>
ap plied</w>
ap lastic</w>
anti viral</w>
anti tumor</w>
anti body</w>
antagon ized</w>
ant ine
ant .</w>
angiotens inogen</w>
anesthe tic</w>
analy ses</w>
an terior</w>
an ,</w>
amphetam ine.</w>
amp icill
amoun ts</w>
amne sia</w>
aminonucleo side</w>
altern ative</w>
alpha 3</w>
alpha 2
al ter</w>
al s,</w>
al pha</w>
al ong</w>
al one.</w>
al located</w>
al bumin
agent .</w>
ag grav
ag e-
af ety</w>
adrenocept or</w>
aden osine</w>
ac tivities</w>
ac tions</w>
ac ri
able ,</w>
abil ity.</w>
a )</w>
[ Na
[ Ca
X )</w>
WR 24
WR24 25
W O
WO RD
WORD S)</w>
V T
VT E</w>
V PA
V P</w>
UN C
UNC AT
UNCAT ED</w>
Thir ty</w>
TR UNCATED</w>
TR AC
TRAC T</w>
TH P</w>
Si x</w>
Se iz
SSR 103
SC r</w>
S/ Q
S event
S afety</w>
S G
S D
R NA</w>
Q S/Q
Pro teinuria</w>
PD T
P ossible</w>
On co
OBJECTIV ES:</w>
O rg
O C
MET H</w>
M ul
M ost</w>
M ).</w>
Long -term</w>
L ID
L );</w>
J ap
In tra
IL- 3</w>
I GF
H ospit
H 2</w>
GN C
GNC 92
GNC92 H2</w>
GABA (A
G er
F S</w>
EC G</w>
E l
E ight</w>
E M</w>
E EG</w>
Compar ison</w>
Com pared</w>
Cardi ac</w>
CPA P</w>
BS TRACT</w>
B lood</w>
Ad di
A b
A T</w>
A E
< 0.00
9 3</w>
9 3
9 0</w>
9 %)</w>
7 H
7 %)</w>
6 7</w>
6 %)</w>
55 4</w>
5-HT 1
5-HT1 B</w>
5 7
4 9</w>
4 7</w>
4 .</w>
3. 6</w>
3- year-old</w>
3 9</w>
3 4</w>
2. 0</w>
2 8</w>
2 6</w>
2 5%</w>
2 /
14 ,</w>
1 %)</w>
1 %),</w>
0.05 ),</w>
0.0 1).</w>
0. 4
. 0
- dose</w>
- dependent</w>
) :</w>
(A BSTRACT</w>
(2 .
(1 -
(0. 5</w>
(+/-)- PG-9</w>
( range,</w>
( c
( 10-
( 0-
z otoc
z he
zhe im
zheim er
zheimer 's</w>
ym al</w>
yl ating</w>
yl ated</w>
yl ate</w>
yl -
year s)</w>
yc in-
xim al</w>
xi let
xilet ine</w>
x -
x ,</w>
weigh t
week ly</w>
viv o,</w>
vie w</w>
vie w
vi gil
ve d,</w>
vaso press
vaso constric
vas ospas
vas odilat
vacu ol
v ular</w>
v an
uti li
ut ing</w>
ure mic</w>
up- regulation</w>
under taken</w>
under sto
unc lear
unclear .</w>
un known.</w>
un its</w>
un it</w>
un il
ul e</w>
u ses</w>
u l</w>
u e</w>
ty- nine</w>
ty ros
tut es</w>
tub er
tuber c
tuberc ulo
tri ax
tri am
tri al,</w>
treat ing</w>
transplant ation,</w>
trans genic</w>
trans cri
trans amin
tr y
topri l</w>
topo side</w>
toge ther</w>
tiv ari
tivari ate</w>
tis m</w>
tion ally,</w>
tin nit
tinnit us</w>
thrombocyto pen
thi ep
thiep in</w>
there fore</w>
ther ,</w>
then ia</w>
th reat
th at
test ,</w>
ter ato
ter al</w>
tem per
techni qu
te lithrom
te d
targ et</w>
switch ed</w>
sur vi
suppress ed</w>
sug ar</w>
sud den</w>
subsequ ently</w>
sub- T
sub-T en
sub-Ten on's</w>
striat um,</w>
strepto zotoc
strate gi
strategi es</w>
stopp ing</w>
stimul i</w>
stat ins</w>
st one</w>
st aining</w>
st ain
st ages</w>
soci ated</w>
small er</w>
sim ult
signific ance</w>
sign al</w>
sig ma</w>
si s;</w>
show ing</w>
short- acting</w>
sh unt</w>
sgk1(+/ +)</w>
sgk1 (-
sensor ine
sensorine ural</w>
sensitiz ation</w>
sel f-
seem ed</w>
sam ple</w>
sal ine,</w>
sal ic
salic yl
s/RD s</w>
s witch</w>
s lic
s ino
sino atrial</w>
ru m</w>
rou s</w>
ropi um</w>
risperid one</w>
ris ks</w>
ri tis,</w>
rh ab
rhab domyolysis</w>
review ed</w>
rest oration</w>
rest om
respon sive</w>
respon se.</w>
resp ect</w>
res er
repe at</w>
ren in-
relev ant</w>
refer red</w>
recor ds</w>
recor ding</w>
rec all</w>
re uptake</w>
re tri
re presents</w>
ratio s</w>
rat ropium</w>
rac hial</w>
ra re,</w>
rTM S</w>
r yo
r y.</w>
r ar
rar a</w>
r .</w>
r ,</w>
question na
qu ine</w>
pt ed</w>
pseudoli thiasis</w>
provi des</w>
prostagland in</w>
prosp ective</w>
propyl thio
proprano lol</w>
prolact inoma</w>
prolact ine
proces s.</w>
pro min
promin ent</w>
pro chlor
prochlor perazine</w>
press ed</w>
present ation</w>
pregn ancy</w>
predic t</w>
prece ded</w>
pre ci
posto per
post synaptic</w>
post dose</w>
posi ti
polymorph ous</w>
point s</w>
po ison
placebo- controlled</w>
piri form</w>
piri de</w>
pilocar pine</w>
phosph or
phenyl ace
phenyl )
ph y.</w>
perio ds</w>
per son
per for
perfor me
pe g
peg ylated</w>
pe ak
paren teral</w>
p.o .)</w>
p-coumar ate</w>
p us</w>
p ont
p ine,</w>
p el
oxy co
oxif ylline</w>
oxid ase</w>
oxic ill
outcom es</w>
ot opic</w>
os por
or ig
or ide</w>
oper ated</w>
op timal</w>
op tic</w>
on .</w>
of loxac
odi lu
od ds</w>
octreoti de</w>
ocicep tion</w>
oc or
o vascular</w>
o pathic</w>
o me
o ma.</w>
o il</w>
o ds</w>
o 4
o4 36
o436 8
o4368 554</w>
nucle oti
noc k
nock out</w>
no d
neurotrans mit
nephro sis.</w>
nephro pathy.</w>
neph ritis</w>
neon atal</w>
necro sis,</w>
ne ural</w>
n one</w>
n igh
multic ent
modafin il</w>
ml )</w>
minut es,</w>
min )</w>
microgram/ kg/
mg/m (2)</w>
mg/kg ),</w>
mg ,</w>
metronid azol
methyl prednisolone</w>
meth yl</w>
meth ods</w>
metabol it
metab olic</w>
medic ation,</w>
me xiletine</w>
me tic</w>
maz indol</w>
man ia</w>
mal form
magnesi um</w>
m es
m E
mE q
locomo tion</w>
lo we
lipo polysaccharide</w>
lin ked</w>
lif e.</w>
li bit
leuk em
l ate</w>
l )</w>
knowled ge,</w>
k nockout</w>
k ind
it ro
it .</w>
iso flur
is ons</w>
is he
ir rig
ip ratropium</w>
iop am
iopam id
iopamid ol</w>
invol ve</w>
investig ating</w>
investig ated.</w>
intro duction</w>
intrac table</w>
intrac aro
intracaro tid</w>
inter f
interf ere</w>
inten sive</w>
injur y,</w>
injec tion,</w>
inhibit ory</w>
ing u
infu sion,</w>
inf used</w>
induc ible</w>
individu als</w>
indic ation</w>
inde x</w>
incorpor ation</w>
in- converting</w>
in s,</w>
in ess</w>
in ese</w>
in es</w>
in :</w>
in 's</w>
illu strates</w>
if ied</w>
identifi ed.</w>
iden tical</w>
id .</w>
ic k</w>
ic k
ic al,</w>
i.v .)</w>
i. c
i.c .
i.c. v
i gh</w>
hy pe
hy de</w>
hum ans</w>
hour s.</w>
hib ition</w>
hepati tis,</w>
hemoly sis</w>
hemo dynamic</w>
hemo dialy
haemorrh age</w>
ha ving</w>
h is</w>
h er
h ap
gradu ally</w>
glyc ine</w>
glut athi
glutathi one</w>
genic ity</w>
gem citabine</w>
gastro intestinal</w>
gabap enti
gabapenti n</w>
ga ret
g/d l</w>
g reg
g no
frac tion</w>
frac t
fol low</w>
fol ate</w>
fo restom
fo od</w>
flu id</w>
fib rin
fi t</w>
femal es.</w>
feed bac
factor s.</w>
f rag
f lestolol</w>
f if
ey e</w>
extrac ellular</w>
expos ure.</w>
experim ent</w>
exp ected</w>
ex tern
evid ent</w>
et y.</w>
estro gen
establ ish</w>
est er</w>
essen tial</w>
es oph
es :</w>
erec tile</w>
epilepsy .</w>
enc y.</w>
en rolled</w>
en larg
en docrine</w>
em erg
elic ited</w>
elev ations</w>
electro physiological</w>
eff ici
ecit abine</w>
earli er</w>
e titive</w>
e osinophil
e le
e asi
easi ly</w>
dysfunc tion,</w>
dur al</w>
doxorub ic
double-bl ind,</w>
document ed</w>
disturb ances</w>
dis co
dis appeared</w>
dipyridamol e-induced</w>
dipyridam ole</w>
differen ti
diet ,</w>
di d
describe d.</w>
deri v
dem enti
del ta</w>
decreas ing</w>
de hyde</w>
de gre
d P
cytot oxic</w>
cyto plasmic</w>
cycl ic</w>
cy an
coun ts</w>
cortis ol</w>
correl ates</w>
correl ate</w>
convul sions</w>
contrac tility</w>
consequ ences</w>
cong estive</w>
concent rating</w>
con current</w>
complic ation.</w>
compar t
compar ing</w>
comp ound</w>
coll icul
coch lear</w>
cocaine- dependent</w>
co- infected</w>
clin icians</w>
clas s</w>
cir rho
ci garet
choline- devoid</w>
cholest a
chol inesterase</w>
ce .</w>
cathe ter
cas es,</w>
caref ul
cardi otoxicity.</w>
carb ox
car e</w>
capsa icin</w>
cannab is</w>
ca using</w>
c u
bo dy
blad der
bet ter</w>
benz odi
bene fit</w>
be ating</w>
basel ine.</w>
bacter ial</w>
b red</w>
b rachial</w>
b r
b it</w>
ax onal</w>
atyp ical</w>
attri buted</w>
atro phy</w>
ation ;</w>
at es.</w>
aster n</w>
assess ment</w>
as thenia</w>
arthri tis.</w>
arrhythmi as</w>
ar yn
ar tic
ar ch
apne a</w>
ap plication</w>
aort a</w>
antipsycho tic</w>
antin ociception</w>
antidepress ants</w>
antibio tics</w>
anti hypertensive</w>
anth rac
antagonist ,</w>
antagon ism</w>
ant ,</w>
angio graphy</w>
angio graph
aneurys ms</w>
anesthe tized</w>
anem ia.</w>
anem ia,</w>
andro gen</w>
and -
analy sis,</w>
analogu e</w>
anaesthe sia.</w>
an other</w>
an om
an olic</w>
an al
anal ys
an -
amplit ude</w>
amphetam ine,</w>
aminotransfer ase</w>
amino phen
amin es</w>
amifost ine</w>
am oxicill
am e</w>
am bul
am .</w>
alpha-methyl dopa</w>
alpha 2-
alle vi
all y.</w>
all ,</w>
alk ylating</w>
al ospor
al one,</w>
al do
al dehyde</w>
agent s,</w>
agent ,</w>
ag greg
ag es.</w>
aff inity</w>
adv ant
administr ation,</w>
aden ocarc
ad d
activ ated</w>
achi eve</w>
accum ulation</w>
ac ic</w>
ac hol</w>
ac cess</w>
ac c
able .</w>
abl ing</w>
ab und
a y.</w>
a emia</w>
a -
[Na ]o</w>
[Ca ]o</w>
[ 3
[3 H
[3H ]-
Z O
X 3
X3 CR
X ,</w>
Warfar in-induced</w>
VN B</w>
V al
US S
USS ION:</w>
U D
Test osterone</w>
TI ENT
T- cell</w>
T AM
St ud
Sim il
Si rolimus</w>
Ser um</w>
S yst
S even</w>
S O
S M-
S D</w>
S ).</w>
Res ults</w>
Rec urrent</w>
R o4368554</w>
R P</w>
R BC
R AS
RAS T</w>
Pre treatment</w>
Pharmaco kine
Ph ase</w>
PR L-
PG E1</w>
PDT C</w>
PA TIENT
PA N</w>
P O</w>
P N</w>
P -
Org an
Onco logy</w>
O ther</w>
O LT
O HD
NS CL
N- methyl-
N itro
N ine</w>
N icot
N either</w>
N a</w>
Mal e</w>
MP T
M in
M eth
M Z</w>
M T
M M
M K-
LY2746 14</w>
L V</w>
L D
L ),</w>
K etamine</w>
K )-
Inc reas
In ter
In hibition</w>
Immuno histo
IS C
ISC USSION:</w>
ID S</w>
I V
I GN
I D</w>
He al
HO E</w>
HB V
H igh</w>
H S</w>
H 2
H )</w>
GABA(A )</w>
G M</w>
F or
F o
El ectro
E astern</w>
E E</w>
D- penicill
D ata</w>
D a
D ISCUSSION:</w>
D 1</w>
Com bin
Co operative</w>
Ch inese</w>
CG RP</w>
CA SE</w>
CA B
C a</w>
C Y</w>
Be fore</w>
BZD s/RDs</w>
BD 10
BC -
BA EP</w>
B P)</w>
B MC
B 12</w>
Al zheimer's</w>
Addi tionally,</w>
Ad verse</w>
AT T-
A to</w>
A rg
A r
A X</w>
A IDS</w>
A BC-
A -
9 ),</w>
9 %</w>
9 %).</w>
8 2</w>
8 +/-
8 %)</w>
7H 6</w>
7 ,</w>
6- week</w>
6- OHD
6 5</w>
6 0
55 5
5 8</w>
5 5</w>
5 ),</w>
5 %,</w>
4- year-old</w>
4- mg</w>
4 ),</w>
3- 4</w>
3 8</w>
3 3
3 0%</w>
20 %</w>
2 9</w>
2 %.</w>
12 )</w>
1. 3</w>
1. 0
1 ;</w>
1 20
1 2-
1 0.
0.00 1)</w>
0.00 1),</w>
0. 5
/ d
/ J</w>
/ 2
/ -</w>
. (ABSTRACT</w>
,4- di
, K)-
+/ -1
) O
(c )O
(P D)</w>
(P <
(Na ,K)-
(N S
( f
( K
( F
( >
( 5.
( 4.
z ido
zido vud
yl l
yl en
yl ase</w>
year ,</w>
yc in.</w>
x anol</w>
worsen ing</w>
wor king</w>
wor k
withdraw n</w>
withdraw al.</w>
warfar in-
war ds</w>
wa y.</w>
wa ve
w sin
vigil ance</w>
vi r
vi gab
vigab at
vi anolic</w>
ven ess</w>
vehic le
ve ment.</w>
ve lop
velop ment</w>
vasoconstric tion</w>
variabl es.</w>
van ishing</w>
valpro ate</w>
v es.</w>
us t</w>
ures ,</w>
ure th
ur inol</w>
ur ia.</w>
ur aemic</w>
unil ateral</w>
unchang ed</w>
un i
un e</w>
un d</w>
un able</w>
ub ated</w>
u ded.</w>
tyros ine</w>
tw o
tur nal</w>
tric ycl
tri fluoro
transpor ter</w>
trans mission</w>
train ing</w>
train ed</w>
tr ated</w>
toler ated.</w>
toler ability</w>
tob ram
to ward</w>
tion -
ticlop idine</w>
tic- uraemic</w>
tic -like</w>
ti ple</w>
ti me
threat ening</w>
thor acic</w>
that ,</w>
tetra hydro
test s.</w>
ter s.</w>
ter odi
ter fen
ter ,</w>
ten d
te rene</w>
te j
te a</w>
tas k</w>
t witch
t s,</w>
t rou
t es.</w>
synerg istic</w>
syn thetic</w>
symptom s,</w>
symptom atic</w>
surger y,</w>
sur ve
sur roun
surroun ding</w>
suppress ants</w>
suppres sion.</w>
sup ra
sup port
sulph asalazine</w>
subun its</w>
sub group</w>
su xamethonium</w>
su m</w>
su ffered</w>
strok e.</w>
stra ins.</w>
stimul ating</w>
stimul ant</w>
ste in's</w>
st ren
stren g
st radi
stradi ol</w>
st ly</w>
st in
squ am
squam ous</w>
spi ronolact
spac e</w>
sp ectively</w>
sp ect
spect rum</w>
som at
smo oth</w>
slic es</w>
sin us</w>
sim vastat
significant .</w>
sign s.</w>
sig ma
side- effect</w>
side s</w>
si veness</w>
si vely</w>
si rolim
shor ten
sh am
sgk1(- /-)</w>
sex ,</w>
ser ve</w>
sensi tivities</w>
semi -
seizure -
seiz ure.</w>
seg ments.</w>
seg mental</w>
sed ation,</w>
secon d-generation</w>
sec tional</w>
se pt
sept al</w>
se p
schizophren ia</w>
schizophren ia.</w>
schedul ed</w>
sar al
saral as
salt- load
salt-load ed</w>
sal vianolic</w>
s low</w>
s ligh
s ha
s ess
s es.</w>
roph il</w>
ron ic</w>
ro se</w>
ro hn
rohn 's</w>
rig id
ri m
retro spectively</w>
retri ev
resto red</w>
respectivel y)</w>
respecti vely</w>
res s</w>
requi res</w>
replac ed</w>
regres sion</w>
regar d
regard less</w>
reduc ed,</w>
recur ren
recover y.</w>
recomm end</w>
reb ro
reach ed</w>
reac tion.</w>
re produc
re present</w>
re ment</w>
re main</w>
re ad
re -
rang ed</w>
radio therapy</w>
ra ther</w>
ra ised</w>
r rol
qu ired</w>
pyridox ine</w>
py rrol
psycho tic</w>
pse udo
protoco l</w>
proteinur ia,</w>
prot ected</w>
proper ties.</w>
prom ot
progres sed</w>
profi les</w>
proced ures</w>
proced ure.</w>
proce du
procedu res.</w>
proca ine-
proca in
proble ms</w>
prob able</w>
pro ximal</w>
pro mis
pro gno
prev ents</w>
pregnanc y,</w>
pregnan olone</w>
preci pit
pre- treatment</w>
pre- test</w>
pre operative</w>
pre lim
prelim inary</w>
pre clinical</w>
prazos in</w>
prazol am</w>
potenti ated</w>
postoper atively</w>
popul ation
poly drug</w>
pol ar
po real</w>
placebo .</w>
pl ed</w>
pl ayed</w>
pit u
phthal mo
phenylace tic</w>
phen om
phenom en
phen ace
phenace tin</w>
ph on
ph an</w>
perio d,</w>
pergol ide</w>
performe d.</w>
per man
pent ylen
pent oxifylline</w>
pent obarbit
pe di
pati al</w>
path ologic</w>
paraly sis</w>
par alle
pap illary</w>
pap er</w>
p neumon
p ine.</w>
p ed
oxyco done</w>
ox y-
outco me.</w>
ous ly,</w>
ot oxic</w>
ost e
oste o
osom al</w>
os yn
os tig
os mol
org ans</w>
or aph
oraph ob
or able</w>
oph thal
on is
on ic
onic id</w>
olog ically</w>
ograph ic</w>
odilu tion</w>
occa sion
ob ut
o z
o ve
o sis</w>
o metric</w>
not ed.</w>
normal ized</w>
normal -
noc turnal</w>
new er</w>
neuro pathy,</w>
ner .</w>
nephro li
negati ve,</w>
need le</w>
ne arly</w>
n ig
n e</w>
n a</w>
n M),</w>
mut ation</w>
multicent er,</w>
morb idity</w>
month .</w>
monit or</w>
ml/ 100</w>
minim um</w>
minim al</w>
min al</w>
mil li
mil k</w>
microg/ side
mg/kg .</w>
mg/kg ).</w>
metopro lol</w>
metabol ite</w>
metabol is
met h</w>
men ing
membran es</w>
medic ation.</w>
medi al</w>
mechanis m
measure ment</w>
me trial</w>
me f
mef lo
mat ter</w>
manifest ation</w>
man ner.</w>
man ,</w>
maint en
mainten ance</w>
macroph ages</w>
m ia,</w>
m arg
m G
mG lu
mGlu R
lymph oma.</w>
lu x</w>
lu minal</w>
lop urinol</w>
log ic</w>
lev ofloxac
lethal ity</w>
le sions.</w>
le g</w>
le d,</w>
lact am</w>
lac k</w>
l s</w>
l ind
l ess
l er
l eng
kin ase</w>
kidne y,</w>
kg (-1
k et
j ud
j u
iz ol</w>
it s.</w>
it al</w>
isoniaz id</w>
isolated-H IT</w>
ir reversible</w>
ir e</w>
ip )</w>
iop rine</w>
io di
iodi xanol</w>
intraperitone al</w>
intramus cular</w>
intramus cul
intra -
intoxic ation</w>
inter ven
inter fer
interfer on</w>
int ub
instill ation</w>
initi ally</w>
ing ly,</w>
ing est
inf iltration</w>
inf ant</w>
inephr ine.</w>
ine d.</w>
ine ;</w>
ine /
individu als.</w>
indic ative</w>
in yl</w>
in ser
impair ments</w>
immuno deficiency</w>
imag ing.</w>
im in
im al</w>
if y</w>
id ation</w>
ic ally,</w>
ic ,</w>
i.c.v .)</w>
i. p.</w>
i. m.</w>
i ven</w>
i th
i on
i es.</w>
i es,</w>
hyperalge sic</w>
hyperalge sia.</w>
hyper prolactine
hydrox y-
hy p
hour s)</w>
hospit al.</w>
hospit al
homo gen
ho od</w>
histor y,</w>
high ligh
hepat ocyte</w>
hel p</w>
hear t.</w>
h loro
gluco cortico
glomerul i</w>
globul in</w>
given .</w>
gi rl</w>
gener ated</w>
gen otyp
gen e-
gamma-H CH
g r
g on
g li
g ain</w>
g .</w>
fut ure</w>
ful l</w>
fu sidic</w>
frac ture</w>
form e</w>
fluo resc
fibrin olysis</w>
facil it
fac t</w>
f le
f in
f ever</w>
f at
f ast
f asc
expos ure,</w>
exist ing</w>
excl uded.</w>
exce ption</w>
exce ed
ex cessive</w>
ex cept</w>
esoph age
esophage al</w>
erythrocy te</w>
erythro id</w>
eryth em
ere sis</w>
epi thelial</w>
enti re</w>
ent s.</w>
endo plasmic</w>
endo metrial</w>
encephalo pathy.</w>
encephalo pathy,</w>
en ed</w>
emplo y
emo tional</w>
emb ryo
em pha
electro encephalo
electro convulsive</w>
el uc
el imin
effici ent</w>
eff ectively</w>
edi atric</w>
ed :</w>
ecti ve,</w>
ect ed.</w>
ear ch</w>
eNO S</w>
e red.</w>
e ligible</w>
e igh
e f
e .
dynam ics</w>
dy stro
dy ston
dro wsin
don or
disorder .</w>
discus sed</w>
discharg e</w>
dis appearance</w>
diff ic
diet .</w>
dic hloro
di ethyl
determin ation.</w>
det ect</w>
det ail
descri b
describ es</w>
des ferri
depri vation</w>
depres sion.</w>
dent ate</w>
del ay</w>
degre es</w>
defer oxamine</w>
dec line</w>
death s</w>
death .</w>
de pressive</w>
day time</w>
day -old</w>
dP /d
dP/d tej
d s,</w>
d ry</w>
d ram
d ine</w>
d ental</w>
d ap
d ;</w>
cysti tis.</w>
cyclospor in</w>
cyclophosphamide -induced</w>
cur cumin</w>
cor rect</w>
contri bution</w>
contri buted</w>
contrac tions</w>
continu e</w>
consum ing</w>
consider ably</w>
consi der</w>
consci ous
conjunc tion</w>
condi tions,</w>
concomit antly</w>
con st
con duction</w>
compris ed</w>
complic ations.</w>
complic ated</w>
comple x</w>
comple ted</w>
compl ained</w>
compens atory</w>
comp etitive</w>
combin ations</w>
com a</w>
com a,</w>
collicul us</w>
collag en</w>
coh ort
coag ul
clozap ine.</w>
clo mipramine</w>
clin ic</w>
cl im
cl ar
cit rate</w>
cis e</w>
cimetid ine.</w>
chloro procaine-
chemo therapeutic</w>
chang es,</w>
chang ed</w>
ch ymal</w>
ceph alospor
cell ular</w>
cell s,</w>
cef triax
cef onicid</w>
cef az
cefaz ed
cathe ter</w>
careful ly</w>
caref ul</w>
carcino gen
carbo platin</w>
carbam azep
carb achol</w>
carb ach
capsa icin-induced</w>
canc er,</w>
c r
c ent</w>
c all
but able</w>
brady cardia.</w>
bor n</w>
block ade
biopsi es</w>
bio psy
bin o</w>
bic arb
bicarb onate</w>
bet al
benzodi azep
bec ame</w>
be ginning</w>
bar ic</w>
b ular</w>
b stein's</w>
b is
b ine</w>
b h</w>
b est</w>
b al
az ath
avoid ed</w>
autoph agic</w>
attri butable</w>
attenu ation</w>
attem pt</w>
attem pt
attac k.</w>
associ ations</w>
asal az
as p
arb am
ar m
ar d
apopto tic</w>
anxi ety</w>
antine oplastic</w>
antibio tic</w>
anti thyroid</w>
anti oxid
anti hyperalgesic</w>
anti convulsant</w>
anti coagulation</w>
anthrac ycl
anom al
ang es</w>
anc er</w>
analys ed</w>
analy ze</w>
analo g</w>
analge sic
analge sia</w>
an encephal
an e,</w>
an dom
amino glyco
amin o</w>
amil oride</w>
amide .</w>
ambul atory</w>
am izol</w>
am ine-
am ent</w>
alpha2 ABC-
alpha- lipoic</w>
aldo sterone</w>
al ways</w>
al lo
al fentan
air way</w>
ain s</w>
aggres sive</w>
agent s.</w>
ag oraphob
ag ain</w>
adult s.</w>
adj unc
adenocarc inoma</w>
ad mission</w>
acet aminophen
acce ler
acc id
ac tion.</w>
ac ross</w>
ac quired</w>
absor ption</w>
abnormaliti es.</w>
ab use</w>
ab stin
[ CI
[ 2-
ZO -1</w>
X3CR 1</w>
X- 2</w>
X .</w>
W ith
U/ L);</w>
U se</w>
U M
UM MA
UMMA R
U C
UC T
UCT ION:</w>
TR I</w>
TM P</w>
TE T</w>
TE R
TAM -induced</w>
TA F
T ran
T en</w>
T RO
TRO D
TROD UCTION:</w>
T NS
T G
T D
TD P</w>
T ,</w>
Stud y</w>
Si gn
SP EC
SG K
SGK 1</w>
S te
S ou
S ex
S UMMAR
S H</w>
Res earch</w>
Re ver
Re duction</w>
R ep
R S</w>
R AM
R ,</w>
QS/Q T.</w>
PT CR</w>
P L
P A</w>
P 120
P .</w>
OLT X</w>
O ral</w>
O P
O D</w>
O )</w>
NO -
N-methyl- D-
N-methyl-D- aspartate</w>
N ational</w>
N AM
N )</w>
My ocardi
Mul tiple</w>
MK- 80
MD A)</w>
M i
M Hb</w>
L- NAM
L- DO
L e
L abor
L .</w>
J une</w>
Im pro
IN TRODUCTION:</w>
IN TER
IGF -
I ts</w>
I T
I N</w>
I F
I .</w>
Hospit al</w>
Heal th</w>
HC F
HA AR
HAAR T</w>
H z</w>
H is</w>
H aem
GSP E</w>
G iven</w>
G SH</w>
G R</w>
F lestolol</w>
F if
F A
FA N</w>
F ,</w>
E1 8.
E valu
E v
E stradiol</w>
E bstein's</w>
E S</w>
E R
E D
E .</w>
Dru g
De velopment</w>
De li
DES IGN
D op
D ex
D SM-
D S</w>
D N
D CE</w>
Coc aine</w>
Ch ronic</w>
Ch anges</w>
Cap sa
CS S</w>
CPA /
CO X-2</w>
CB Z</w>
CA )</w>
C yclo
C urrent</w>
C ur
C s
C rohn's</w>
C or
C lo
C entr
C ancer</w>
C al
C X3CR1</w>
C T</w>
C N</w>
C M
C 57
C57 B
C .</w>
BC N
B NP</w>
B A</w>
B 2</w>
B )</w>
An gi
An aly
ATT- ALF</w>
AT T</w>
AT P</w>
AC h</w>
A u
A t
A g</w>
A 1</w>
A /J</w>
8. 9</w>
7. 0</w>
7- year-old</w>
6 ).</w>
555 62</w>
5- hydroxy
5- Az
5 9</w>
4 50</w>
3. 3</w>
3. 0
3 1</w>
3 00</w>
3 ,
3 ).</w>
3 %).</w>
27 %</w>
2- chloroprocaine-
2- 3</w>
2 D
17 beta-
15- minute</w>
1/ 2</w>
1. 6</w>
1 6.
1 50</w>
1 5.
1 40</w>
1 -1
0.0 1
0. 6
0. 3</w>
0. 3
-H IV</w>
- positive</w>
- operated</w>
(p H</w>
(S BP)</w>
(S ):</w>
(P =
(O R
(Na,K)- ATPase</w>
(N MDA)</w>
(HB V)</w>
(A D
(9 5</w>
(6 )</w>
(3 ,4-
(2. 0</w>
(2 -
(1 50</w>
( up</w>
( given</w>
( a</w>
( PAN
( MA
( EC
( <
( 40</w>
( 4-
z onis
z ep
z ation</w>
youn ger</w>
yl transfer
year s;</w>
yc in-induced</w>
y- increasing</w>
y tid
ytid ine</w>
y ;</w>
xi ous</w>
x es</w>
x anth
x .</w>
wom en
wh at</w>
weight )</w>
week s)</w>
we l</w>
we l
wel ve</w>
warfarin- drug</w>
wa ve</w>
w ise</w>
w is
w ide</w>
w av
wav es</w>
w ant
want ed</w>
volu me.</w>
volu me,</w>
voc al</w>
vit y,</w>
vit ro
vir tu
vi ation</w>
vessel s</w>
ves se
vesse l</w>
ver .</w>
ventil ation</w>
ven s-
vens- J
vens-J o
vens-Jo hn
vens-John son</w>
vel y,</w>
ve red.</w>
ve loc
vasospas m</w>
vasopress in</w>
variabl es,</w>
vari ety</w>
vari ed</w>
vari ants</w>
vari able</w>
valu es.</w>
valpro e
valproe x</w>
val vular</w>
v or
v ino
vino rel
vinorel bine</w>
v ical</w>
v ar
v age</w>
v ag
uter o</w>
uter ized</w>
uter ine</w>
ut com
ush -
ush- evoked</w>
use d.</w>
us ulf
urg ent</w>
uracil .</w>
ur ic</w>
uni que</w>
understo od.</w>
unchang ed.</w>
unchang ed,</w>
unc ular</w>
unc er
un known</w>
un it
unit ,</w>
un event
un affected</w>
ul cer
uc us</w>
uc hen
uchen ne</w>
u sion-
usion- weighted</w>
u si
usi ve.</w>
u ation</w>
u ary</w>
tw o-
tw in</w>
tur no
turno ver</w>
tumor s.</w>
tuberculo sis</w>
tub ules</w>
tu tion</w>
tro p
tro le
trole andom
tricycl ic</w>
triam terene</w>
tri mo
trimo x
tri gem
tri als</w>
tre n
transplant ed</w>
trans fusion</w>
trac h
trach lor
toler ated,</w>
toge ther,</w>
to m
to genic</w>
tissu es.</w>
tion :</w>
timo lol
ticlop idine-induced</w>
tic s,</w>
tic -induced</w>
ti ve.</w>
ti trated</w>
ti t
thou ght</w>
there af
ther s</w>
the l
thal amic</w>
th us,</w>
th o
th is,</w>
th ick
th es
tern ational</w>
ter ms</w>
tend ency</w>
temper at
telithrom ycin</w>
te trachlor
te d,</w>
target ed</w>
tachy cardia,</w>
table ts</w>
ta il</w>
t ru
tru e</w>
t es,</w>
t al
t ain
t ail
tail -
system s</w>
system ,</w>
susp ected.</w>
sus pen
surve ill
surveill ance</w>
support ing</w>
supple ment</w>
super oxide</w>
sul in
sulin da
sulinda c</w>
suc rose</w>
suc cin
succin ylcholine</w>
substi tution</w>
subst ance</w>
sub set</w>
sub clinical</w>
su ic
struct ures</w>
struct ure</w>
struct urally</w>
stron g
strong ly</w>
stret ch
strate g
stopp ed</w>
sti l
stil be
stilbe stro
stere otyp
stat e.</w>
stand ing</w>
st om
st a
spironolact one</w>
specimen s</w>
spec ific
spas tic
spar te
sp e
some times</w>
sol id</w>
soci al</w>
smok ers</w>
sligh tly</w>
sk ill
simult aneously</w>
side- effects</w>
si zed</w>
si ent</w>
si ci
sici ans</w>
si an</w>
shor ter</w>
sham -operated</w>
sh oc
sh ap
sever ity.</w>
seroton ergic</w>
ser ved</w>
ser ial</w>
sequela e.</w>
sel ectively</w>
sel ection</w>
seg ments</w>
se tting</w>
se ter</w>
scopol amine.</w>
sco re.</w>
salt- deple
salicyl ic</w>
s.c .</w>
s- -
s w
s ought</w>
s lowing</w>
s low
s light</w>
s clero
s can
s atis
s a</w>
s P120
ru sion</w>
ru pt
ro tox
ro striatal</w>
ro d
rit od
ript yl
rib osomal</w>
ri f
rif amp
ri es</w>
rh es
rhes us</w>
reversib ility</w>
rever sal</w>
retro viral</w>
retro spective</w>
retriev al</w>
reticul um</w>
result s.</w>
respon se,</w>
respon ding</w>
respon ded</w>
resp ective</w>
reser pine</w>
rese m
res ,</w>
replac ement</w>
renin- angiotensin</w>
ren zep
ren ovascular</w>
reli ef</w>
releas ing</w>
rel im
rej ection</w>
regi on</w>
reg ist
recommen ded.</w>
receptor s,</w>
receptor -
reas on
reas .</w>
reac tions,</w>
re presented</w>
re organization</w>
re mo
re mark
re ati
raz epam</w>
rang e.</w>
radi ation</w>
rac lon
rab bit</w>
ra rely</w>
ra m</w>
ra dic
ra d
rad ical</w>
r inary</w>
r in.</w>
r in,</w>
r ically</w>
r amine</w>
quinol ine</w>
quin ol</w>
qu ad
pyrrol ate</w>
put ative</w>
punct ate-
punctate- evoked</w>
psych os
provo ked</w>
prot in
prosp ective,</w>
prophyl ax
prolifer ative</w>
progres sion.</w>
prof loxac
proced ure</w>
procain amide</w>
pro thrombotic</w>
pro posed</w>
pro pa
propa fen
pro gn
progn os
prognos tic</w>
pro found</w>
pressu res</w>
present ,</w>
pres um
pres er
premat ure
pregnanc y.</w>
predomin antly</w>
predis posed</w>
predic t
pre- existing</w>
pre treatment.</w>
practi tion
pr ick</w>
pp ing</w>
potenti ation</w>
post ulated</w>
possib le.</w>
posi tion</w>
poor ly</w>
pont ine</w>
polys om
polysom no
poly uria</w>
poin ter</w>
po ro
po i
poi e
pl u
pl at
piroxic am</w>
pilo t</w>
pic rotox
pi renzep
physici an</w>
physi ologic</w>
phenyl) ethyl
pharmaco dynamic</w>
perman ent</w>
perio dic</w>
peri vascular</w>
perc utaneous</w>
per in
pentylen e
pentobarbit al</w>
pent az
pentaz oc
pen ia.</w>
pedi atric</w>
ped uncular</w>
peak ed</w>
patient s;</w>
patient s),</w>
path way</w>
path way.</w>
parame ters.</w>
paralle l</w>
para di
paradi g
par at
par asym
parasym pathetic</w>
par amethasone</w>
pall idal</w>
pal sy</w>
pa rox
pa infu
painfu l</w>
pa fo
pafo x</w>
p.o .,</w>
p.o .
p tive</w>
p ly</w>
p ine-treated</w>
p in
p ill
p g/
p <0.00
p <0.0
oxygen ation</w>
oxy- 4-
ox ant
ox amine.</w>
ov ine</w>
outco me,</w>
out put
ous tic</w>
otoxic ity,</w>
ot s</w>
ot o
ost aining</w>
os ar
oro facial</w>
or i
or bit
orbit al</w>
opi oid</w>
opi oid
oph osph
open -
onucle ar</w>
on ly.</w>
ome prazol
om er
om as
ol ig
ol g
olg i</w>
ograph y</w>
off er</w>
oclon al</w>
occasion ally</w>
obt ain</w>
obstruc tive</w>
ob last
o sis,</w>
o quinol</w>
o d,</w>
nucleoti de</w>
nucle i</w>
nucle ar</w>
non small</w>
no xious</w>
no w</w>
nitroprus side-induced</w>
nitro -
nitrendi pine-treated</w>
nimodi pine</w>
nig rostriatal</w>
ng/ mou
newbor n
neuron s.</w>
neuro psychiatric</w>
neuro physiological</w>
neuro cognitive</w>
nephro toxicity.</w>
nephro toxicity,</w>
nephro pathy,</w>
neon ates</w>
neon ates.</w>
necro sis.</w>
ne ur
ne oplastic</w>
ne ither</w>
nalox one</w>
my asthenia</w>
multi forme</w>
mul tivariate</w>
mt DN
mou th,</w>
mou th
morph ology</w>
morph ine.</w>
mor ning</w>
mon onuclear</w>
mon oclonal</w>
modi fied</w>
model ,</w>
mo thers</w>
mo ther</w>
ml/ min</w>
mitochond ri
mit ral</w>
mit oxant
mis sion,</w>
min ant</w>
min -1</w>
min -1
min ,</w>
mil d-type</w>
migra ine.</w>
midd le-
middle- aged</w>
mid azol
microg/ kg)</w>
microg li
micro vascular</w>
mg/m 2/
mg/m 2,</w>
mg/ day
mg/ K
metronidazol e-induced</w>
metronid azole</w>
methyl ation</w>
meth oxy-4-
meth od.</w>
meth od
meth ac
metabolit es</w>
metabol iz
met oc
met amizol</w>
medull ary</w>
medi um</w>
medi ating</w>
mechanis ms.</w>
meas uring</w>
meas ures</w>
me l
me ans</w>
mat er
mater nal</w>
mas seter</w>
man .</w>
mal e,</w>
mal e
maint ain</w>
mT o
mRN As</w>
mEq /
m uch</w>
m on</w>
m mol/
m im
m L/
m 2</w>
m .,</w>
ly )</w>
lu pus</w>
lowe red</w>
los s,</w>
loc us</w>
lo fen
literat ure,</w>
lim it</w>
lim b</w>
lif e-
life- threatening</w>
lidoca ine.</w>
libit um</w>
leuk o
lead s</w>
le ven</w>
le ,</w>
lat eral</w>
last ed</w>
larg er</w>
lamivudine- resistant</w>
lact ate</w>
la betal
l ay
lay er</w>
l a</w>
l (-1
k- diff
k-diff usion,</w>
k ,</w>
jud g
j o
j aundice</w>
iz ation.</w>
iti al</w>
it y-increasing</w>
it riptyl
it ect
ischem ia</w>
ischem ia.</w>
ischem ia,</w>
is su
ir rit
invol ving</w>
invol ves</w>
invol vement.</w>
investig ation</w>
intracor poreal</w>
intracor onary</w>
intra der
intoxic ation.</w>
inter view
inter peduncular</w>
inten si
int act</w>
inst em</w>
insi pid
initi es</w>
inhibi tion.</w>
ing s,</w>
ing ),</w>
infu sional</w>
inflam ed</w>
infec tion.</w>
ine ly</w>
ine a</w>
ine -</w>
ine )</w>
increas ed.</w>
in- releasing</w>
in- ezetimi
in- based</w>
in z</w>
in nerv
in dependently</w>
in bred</w>
in avi
impair ment.</w>
immunosup press
imag es</w>
im age</w>
ill ing</w>
ific ant</w>
idi opathic</w>
id -
ic in.</w>
ia :</w>
i.p. ,</w>
i.p. ).</w>
i. e
i.e .,</w>
i sual</w>
i dis
i .</w>
hypox ia</w>
hypo the
hyper kine
hyper baric</w>
hyper activity,</w>
hype re
hydroxy phenylacetic</w>
hydro gen</w>
hydro chlor
hy sicians</w>
hist ologic</w>
her bal</w>
hepat ocytes</w>
hepar in-induced</w>
hepar an</w>
hemodialy zed</w>
hemo globin
headache .</w>
hap to
hal f-
haemoly tic-uraemic</w>
haem odilution</w>
habit ual</w>
h or
h il
h )</w>
gy nec
gu inea</w>
group s:</w>
group )</w>
group ).</w>
granulomato sis.</w>
granulomato sis,</w>
granulo cy
gra ft</w>
gra dual</w>
glyco pyrrolate</w>
gluc ar
gi ving</w>
gamma-H C
gamma-HC H</w>
gam ma</w>
g/ day</w>
g/ d</w>
g um.</w>
g ment
g io
g ated</w>
g ,</w>
func tion,</w>
ful minant</w>
fu sion,</w>
frag ment
fract ures</w>
four th</w>
form s</w>
form ed</w>
forestom ach</w>
follow- up.</w>
foc us</w>
fluoxet ine</w>
fluoxet ine-induced</w>
fluoro carb
fluoresc ent</w>
fluo res
fl ush
first- time</w>
fibrill ation.</w>
fib rin</w>
fi x
fet uses</w>
fentan yl
fe ren
fav orable</w>
facil itation</w>
f uro
f re
f low
f il
extrac t</w>
extern a</w>
exten ded</w>
exten d</w>
explor atory</w>
expl ain</w>
experiment s,</w>
exer ts</w>
exer ci
examin ations</w>
ex pressed</w>
ex cess</w>
ex amine
ex amic</w>
eti ology</w>
estrogen -induced</w>
es cal
es /
erythrocy tes</w>
ery l</w>
erg on
er ap
episo d
epile pto
enzym es,</w>
ent h</w>
encephalo path
en tial</w>
en si
en ergy</w>
en ding</w>
en coun
encoun tered</w>
en chymal</w>
emergen ce</w>
emerg ent</w>
em is
em ia.</w>
em ia,</w>
elimin ation</w>
electrocardio graphic</w>
elder ly.</w>
el y,</w>
el l</w>
el ation</w>
effect ,</w>
eff lux</w>
ecti ve.</w>
echocardiograph y.</w>
ec tion.</w>
ec tion,</w>
e toposide</w>
e g
e ated</w>
dystro phy.</w>
dysfunc tions</w>
dysfunc tions.</w>
dram atically</w>
doxorubic in-treated</w>
dou ble</w>
dose- response</w>
dose- limiting</w>
dose- dependently</w>
dose )</w>
dos ing</w>
dos ed</w>
dos ages</w>
dop amine-
don or</w>
disulfi ram</w>
dist ingu
disorder s,</w>
diseas e:</w>
discus s</w>
disco vered</w>
dis played</w>
dis abling</w>
diltiaz em,</w>
diff use</w>
diethyl stilbestro
did an
dichloro phenyl)ethyl
di valproex</w>
di uretic</w>
di ure
di men
dexameth as
deteri or
deter m
describe d,</w>
deri ved</w>
deple tions</w>
depend ency</w>
depen d</w>
depart ment.</w>
demon strat
dementi a</w>
del ine
defect s.</w>
death ,</w>
de viation</w>
de pos
de af
de -induced</w>
days )</w>
dat a,</w>
dam aged</w>
dail y)</w>
dP/dtej c</w>
d or
d in
d )</w>
cyto chrom
cytochrom e</w>
cy t
cur rently</w>
cult ures</w>
creat in
coun ter</w>
coun t</w>
cortis one</w>
corticosteroid s.</w>
cortex ,</w>
control led,</w>
contribut ing</w>
contraceptiv es.</w>
cont ained</w>
const ant</w>
consequ ence</w>
confoun ding</w>
condi tions.</w>
concentr ation.</w>
compon ents</w>
complic ating</w>
compar isons</w>
comp uterized</w>
com pa
coca ine,</w>
co- trimox
co vor
co u
co st-
co lon
co id
clonid ine.</w>
clonid ine,</w>
clo ti
clim bing</w>
cli oquinol</w>
classi fied</w>
clar ify</w>
cit alo
cis apri
cir cum
cigaret tes</w>
ci profloxac
cholesta sis.</w>
cholest eryl</w>
chloro fluorocarb
child hood</w>
chic ks</w>
charg e</w>
channe ls</w>
chang e,</w>
ch elation</w>
cerebell um</w>
cell ulo
ce t
catalep sy
caro ta</w>
cardiom y
cardio respiratory</w>
cardio protective</w>
carcin omas</w>
carbach ol,</w>
carb im
cap ecitabine</w>
cap ac
capac ity</w>
call ed</w>
calc ulated</w>
caffe ine.</w>
c los
c lear</w>
but am
bupivaca ine.</w>
bromocript ine-induced</w>
bre ath
bra in.</w>
bra in,</w>
br ush-evoked</w>
bo y</w>
bo wel</w>
bo th.</w>
block .</w>
bladder .</w>
bl ing</w>
biopsi es
biliru bin</w>
beta- blockers.</w>
beta ENaC</w>
benz o
behavior s.</w>
behavi our</w>
behavi o
bec ome</w>
bac k-diffusion,</w>
b er
azol e.</w>
azepam ,</w>
azath ioprine</w>
az an
azan avi
autoph ag
autophag y</w>
auto antibodies</w>
attenu ate</w>
atherosclero sis.</w>
ate -induced</w>
at ors</w>
at ological</w>
at es,</w>
at azanavi
astro cy
ass ay.</w>
asp ects</w>
as sum
as se
as cit
arth ro
aro und</w>
arch itect
ar ization</w>
aph eresis</w>
ap raclon
ap parat
anxi ety.</w>
antipsycho tic-like</w>
anti- inflammatory</w>
anti retroviral</w>
anti oxidant</w>
anti cholinergic</w>
anti cancer</w>
anti arrhythmic</w>
antagonist s.</w>
ant ly,</w>
ant -induced</w>
angiotens in-converting</w>
angiograph y.</w>
ang ina</w>
aneurys ms.</w>
anesthe sia
anc es,</w>
an uary</w>
ampicill in</w>
amoxicill in</w>
amivud ine</w>
amiodar one,</w>
aminonucleo side-induced</w>
amide -induced</w>
amelior ated</w>
am mon
am itriptyl
alpha ENa
alphaENa C,</w>
alpha 5</w>
alpha 1-
alpha1- adrenergic</w>
alk aline</w>
alfentan il
alco h
albumin uria</w>
al prazolam</w>
al low
al it
al bino</w>
agon ists</w>
ag ing</w>
aff inities</w>
adriamyc in-treated</w>
adriamyc in-induced</w>
administ ered.</w>
adjunc tive</w>
add ress</w>
activ ity-increasing</w>
activ ation,</w>
activ ate</w>
act in
acromegal y</w>
acromegal ic</w>
acid osis,</w>
acet ylcholinesterase</w>
accoun ting</w>
accid ental</w>
ac oustic</w>
ac it
ac cur
abund ance</w>
abs ent</w>
abnormaliti es,</w>
abil ities</w>
ab using</w>
ab use.</w>
a protin
a ine-induced</w>
a .
[2- (3,4-
[2-(3,4- dichlorophenyl)ethyl
Y :</w>
WS R</w>
WS P</w>
WR2425 11</w>
W or
W I</w>
Val pro
VP U</w>
VP A</w>
V isual</w>
V ari
V A
UD Y</w>
U/ l,</w>
U rinary</w>
U T
UT CO
UTCO M
Twent y</w>
Tran sient</w>
Thirty- five</w>
TM A</w>
TI NG
TG ,</w>
TE E</w>
TE )</w>
T rial</w>
T otal</w>
T J
T G</w>
T CR</w>
Syst olic</w>
Sub sequ
Su xamethonium</w>
Ste vens-Johnson</w>
Sou th</w>
Simil arly,</w>
Sign ificant</w>
Sex ual</w>
Seiz ure</w>
SUMMAR Y:</w>
ST UDY</w>
SSR103 800</w>
SO CS
SE .</w>
S yn
S wis
S ul
S odium</w>
S oci
S h
S ch
S T-
S N
S ET
SET TING
S D)</w>
S A</w>
S A
S -
S (c)O
Rep eated</w>
Rec ur
Rec ently,</w>
Rec ent</w>
Re por
RBC s</w>
RAM H</w>
R is
R 13
R13 2</w>
R -
Pharmacokine tic</w>
Ph en
PG- 9
PATIENT S</w>
PA )</w>
P< 0.05),</w>
P renatal</w>
P ost
P hysicians</w>
Organ ization</w>
On ly</w>
O utcom
O phthalmo
O c
O UTCOM
O R
O AE
O -
Nicot ine</w>
Ne ph
Na+ -
NT E</w>
NF kappaB</w>
NF -
Myocardi al</w>
Mor ph
Mi pafox</w>
MT X</w>
MR Is</w>
MP EP</w>
MD MA</w>
MA P</w>
MA IN</w>
M edi
M ar
M any</w>
M P</w>
M D</w>
Li ver</w>
Li thi
Labor atory</w>
L- alpha-
L amivudine</w>
L R132</w>
L H</w>
L A
K e
J anuary</w>
Intrac ranial</w>
Intra venous</w>
Increas ed</w>
In ternational</w>
In itial</w>
IS O</w>
IN G
ING S:</w>
IN D
IND INGS:</w>
II )</w>
IGF- IL-3</w>
IC P</w>
I- S
I U/l,</w>
I II</w>
I CA
I 1-
I ,</w>
He re,</w>
He pati
He inz</w>
HC a</w>
HBV -HIV</w>
HB e
H2 O</w>
H ere</w>
H E
H .</w>
GA BA</w>
G olgi</w>
G la</w>
G en
G 14
G14 5
G145 R</w>
For ty-
Fo od</w>
FANF T</w>
F our</w>
F isch
F e
F an
F L</w>
F L
F INDINGS:</w>
F 344</w>
En do
En d-
ET -1</w>
ESRD ,</w>
E pi
E leven</w>
E lev
E ach</w>
E L
E B
E -
E ),</w>
Drug -induced</w>
Differen tial</w>
Di rect</w>
Dex amethasone</w>
Deli rium</w>
Da ucus</w>
DF P</w>
DESIGN :</w>
D uchenne</w>
D is
D ec
D ays</w>
D WI</w>
D ES</w>
D 4.
Cyclo phosph
Cs A</w>
Combin ed</w>
Ch ol
Centr al</w>
Capsa icin</w>
Cap topril</w>
CaCl(2)- treated</w>
CYP 3
CYP3 A
CYP 2D
CPA/ EE</w>
CH F</w>
CD 4
CD4 +</w>
CD 36</w>
CA 1</w>
C57B L/
C ros
C lon
Bra in</w>
Bas el
BCN U</w>
BB B</w>
BB B.</w>
B io
B R</w>
B P,</w>
B ID</w>
B ,</w>
At ten
Analy sis</w>
An gio
Al pha
Af ric
Ab normal</w>
AI M
AD C</w>
AC h
A ra
A p
A cet
A VP</w>
A E</w>
A A
93 12
9 4</w>
9 0
9 ).</w>
8- year-old</w>
8 6</w>
8 5</w>
8 4</w>
7. 5%</w>
7 6</w>
7 0-
7 %).</w>
6-OHD A</w>
6 7%</w>
6 3</w>
6 0%</w>
6 -induced</w>
6 ),</w>
6 %,</w>
6 %),</w>
50 6</w>
50 6-induced</w>
5. 0</w>
5-hydroxy try
5-F U
5-Az C</w>
5- az
5 ;</w>
5 4</w>
5 1</w>
4 5</w>
4 %)</w>
3. 2</w>
3. 0</w>
3 3</w>
3 2.
3 ,4-di
3,4-di hydroxyphenylacetic</w>
3 %)</w>
3 %),</w>
2. 4</w>
2. 1</w>
2- minute</w>
2, 2,
2 6.
2 4.
2 -</w>
2 %;</w>
2 %).</w>
19 .
19 %</w>
18 0</w>
18 ,</w>
17 %</w>
13 5</w>
13 1
10(- 3)</w>
10 00</w>
10 0-
10 ,000</w>
10 )</w>
1. 4%</w>
1. 1-
1- year</w>
1- 10</w>
1 6,</w>
1 6%</w>
1 5%</w>
1 1,</w>
0.00 0
0. 8</w>
0. 8%</w>
0. 6</w>
0. 5,</w>
0. 4</w>
0. 2
/ M
-1 .</w>
-1 -
- based</w>
+ 2</w>
) ).</w>
) ),</w>
(p =
(R R</w>
(P =</w>
(3 )
(2 0</w>
(10- 40</w>
(10 %)</w>
(1 1</w>
(1 1.
(1 )</w>
(0. 2</w>
(0. 1</w>
(0. 1-10</w>
( one</w>
( median</w>
( i.e.,</w>
( group</w>
( e.
( at</w>
( SR
( 7.
( 60</w>
( 4</w>
( 0.0
( +
( "
' -
zonis amide.</w>
zidovud ine</w>
z one</w>
z en</w>
ys tic</w>
yr ylcholinesterase</w>
yr us,</w>
yr -old</w>
yn ap
ynap tic</w>
yll ine.</w>
yl thio
yl ation</w>
yl )</w>
ycin- mediated</w>
y- stimulating</w>
y- specific</w>
y s.</w>
y ric</w>
y ri
yri dam
y pi
y lo
ylo id</w>
y i
yi el
y g
yg ous</w>
y /
xim ide</w>
xanth ine</w>
xamethoni um,</w>
x ine</w>
x )</w>
worsen ed</w>
work ers</w>
wor k-
weigh ts</w>
we d.</w>
we an
wave forms</w>
warran ted</w>
warran ted.</w>
warfar in.</w>
w k</w>
w all
volunte er</w>
volum es</w>
vit real</w>
vincrist ine</w>
vigabat rin</w>
vi sion</w>
vi ously</w>
vessel s.</w>
verapamil .</w>
ver sion</w>
ver ages</w>
ventil ated</w>
ven ile</w>
veloc ity</w>
ve st
ve )</w>
ve '
vasodilat or</w>
vari ability</w>
var ying</w>
valu e.</w>
val ve</w>
val idity</w>
vacu ous</w>
v x</w>
v ity</w>
v ic
v al</w>
utili zation</w>
ut ri
utri tional</w>
ut ed</w>
ut aneously</w>
ust er</w>
us ti
us h</w>
us ers,</w>
us cit
us -associated</w>
ureth ral</w>
ures .</w>
ure :</w>
ur so
urso deoxy
ursodeoxy chol
ursodeoxychol ic</w>
ur se</w>
ur ium</w>
ur ation</w>
up dat
unevent ful</w>
und us</w>
und le</w>
un wanted</w>
un usually</w>
un ted</w>
un likely</w>
un g
un common</w>
um- 20
um-20 1</w>
um er
ultra -
ultra- short-acting</w>
ulo pathy</w>
ulf on
ul tho
ultho od.</w>
ul es,</w>
ul ate</w>
ul ar
ul anic</w>
udi es</w>
ud a</w>
uc lear
uclear -
uc l
ucl ide</w>
uc asi
ucasi an</w>
ub ular</w>
ub le</w>
u tility</w>
u sive</w>
u propion</w>
u ated</w>
typ es,</w>
ty- five</w>
two ;</w>
twitch ing</w>
tut ed</w>
tum our</w>
trou gh
trough -
trough- concentrations</w>
troleandom ycin-induced</w>
tro ph
tro ke</w>
tri g
tri azol
tri al
trial :</w>
treatment -related</w>
treat ed,</w>
transplant ations</w>
transplant ation
transfer red</w>
transamin ases</w>
trans verse</w>
trans thoracic</w>
tran examic</w>
trac er</w>
tra um
tra n</w>
tr icep
tr amine</w>
tot em
totem por
totempor al</w>
tot ally</w>
tor r,</w>
ton gu
toco ph
tocoph er
tobram ycin</w>
to ol</w>
to o
too k</w>
to mo
tomo graphy</w>
to id</w>
to bac
tobac c
tobacc o</w>
tiz ation</w>
tiz an
tis m.</w>
tim ul
ticlop id
tic ,</w>
ti tion</w>
ti ght</w>
ti es,</w>
thyro idis
thym ocyte</w>
thym idine</w>
thym ic</w>
thromboembol is
thrombo sis.</w>
thir d-generation</w>
thi azol
thereaf ter.</w>
there by</w>
therap y:</w>
theoph ylline.</w>
the ore
thal li
thalli um-201</w>
thal asse
th em
th al</w>
th -
tetrahydro py
tetrahydropy ran
tetrahydropyran yl
tetrachlor ide</w>
tetra z
terfen adine</w>
terato genic</w>
ter s/
ters/ B
ters/B W</w>
ter mat
ter ic</w>
ted ly</w>
te t
te red.</w>
te ar</w>
te -
tas k.</w>
tak e</w>
tacrolimus -associated</w>
tacrolimus )</w>
t one</w>
t ing.</w>
t ation</w>
t ase</w>
t ari
t PA
synerg y</w>
syndrom es</w>
suspen sion</w>
surviv ors</w>
survi val
supra ventricular</w>
suppress ants.</w>
supplement ed</w>
sup ine</w>
sulph ate</w>
sulf asalazine</w>
sul piride</w>
sugg estive</w>
success ful
successful .</w>
suc cessive</w>
suc cess</w>
subun it</w>
substi tutes</w>
substanti ally</w>
subst rate</w>
subject s,</w>
subc utaneously</w>
sub strat
sub ling
sub groups</w>
sub acute</w>
su tism</w>
su mm
stud ying</w>
striat um.</w>
stri p
stret ch</w>
stres s.</w>
strateg y</w>
stopp ed.</w>
ston es,</w>
stimul atory</w>
stimul ation.</w>
stimul ated</w>
steroid al</w>
stere ot
stain ing,</w>
st er</w>
st ep</w>
st ent</w>
st ent.</w>
st en
st ed</w>
st atic</w>
st atic
st ates</w>
st ability</w>
st abil
st .</w>
squ are</w>
spec ies</w>
spec ial</w>
spe ed</w>
spar ing</w>
sp ring</w>
son e-
somat ost
somatost atin</w>
solu tion,</w>
sol uble</w>
sol itary</w>
smok ing,</w>
slow ly</w>
skill ed</w>
sit u
simvastat in-ezetimi
simil arly</w>
sim ple</w>
significant ly.</w>
sigma 1</w>
side ,</w>
si tive</w>
si ded</w>
si as</w>
shorten ed</w>
short ly</w>
shoc k</w>
shi fts</w>
shi ft</w>
shi f
she l
shap e</w>
sevoflur ane,</w>
seve re.</w>
seri es.</w>
sequela e</w>
sequ ential</w>
separ ated</w>
sensitiz ation;</w>
sensi tiv
sens ation</w>
semi- quantitative</w>
sel ecti
selecti ve'
seizure- inducing</w>
seg ment</w>
seg ment
sec tions</w>
se udo
se ts</w>
se en.</w>
se ed</w>
scor ing</w>
sclero sis</w>
schizophren ic</w>
scal e.</w>
scal e,</w>
sc ab
sal vage</w>
sal butam
sa des</w>
sP120 T</w>
s- per
s-per ill
s-perill yl</w>
s patial</w>
s or
s one</w>
s odi
s ati
sati le</w>
s at
s acri
sacri fic
s G145R</w>
s Ag
s -induced</w>
s -1</w>
ry po
rout inely</w>
rod ents</w>
ro zen</w>
ro o
roo m</w>
ro l</w>
ro dent
rodent s.</w>
ritonavi r.</w>
ritod rine</w>
risperid one.</w>
rigid ity,</w>
rifamp in</w>
ri t</w>
ri l
ril men
rilmen idine</w>
rheumat ologic</w>
revie wed.</w>
restric tive</w>
rest or
restor e</w>
rest ing</w>
resem bling</w>
resc en
rescen tic</w>
res uscit
res ection</w>
reproduc i
rem or</w>
reli eved</w>
rele ase,</w>
relap se</w>
regul ation.</w>
regist ered</w>
regimen ,</w>
reg ard</w>
refl ected</w>
refl ect</w>
reduc tase</w>
recogn ition</w>
reco vered.</w>
recipi ents.</w>
recipi ent</w>
rec tom
rec re
recre ational</w>
reas on</w>
re plic
re ments</w>
re ma
rema ind
re ement</w>
re arm</w>
rat s:</w>
rat ings</w>
rat a
rata eg
rataeg us</w>
random ised</w>
ran ulo
ran t</w>
ram -like</w>
radi oph
radi on
radion uclide</w>
radi ographic</w>
radi al</w>
ra p
ra ise</w>
ra i
r un
r ul
r t
r sutism</w>
r one</w>
r ated</w>
r /
r/ ritonavir</w>
questionna ire</w>
questionna i
qu ater
quater n
quatern ary</w>
qu alit
pyri mid
pyrimid in
pul satile</w>
pto phan</w>
psychos timul
psych ological</w>
prote ase</w>
prot ect
proprano lo
prophylax is</w>
propafen one</w>
promis ing</w>
prom pt</w>
progres sively</w>
prof en</w>
produc ts.</w>
produc tion.</w>
produc ing</w>
produc es</w>
process ing</w>
pro thrombin</w>
pro be</w>
pro anth
proanth ocyan
proanthocyan id
previ ously.</w>
previ ously,</w>
pressu re.</w>
press or</w>
preser ved</w>
present ation.</w>
present ation,</w>
pres ynaptic</w>
prepar ations.</w>
premature ly</w>
pregnan -
pregnan- 20-
pregnan-20- one
prefer red</w>
predomin ant</w>
predn is
predis pos
predispos ing</w>
predict ors</w>
pre neoplastic</w>
pre hen
pre ference</w>
pre feren
praz ole</w>
practition ers</w>
pra m</w>
potenti ates</w>
potenti ate</w>
potenti als</w>
post- CAB
post ural</w>
positi vely</w>
port antly,</w>
popul ation.</w>
popul ation,</w>
point es</w>
poie tin</w>
po w
pneumon ia</w>
ple x
ple ural</w>
ple k
plek h
plekh h
ple as
placebo- controlled,</w>
plac em
pl ant</w>
pl ain</w>
pl a
pla sia</w>
pivac aine</w>
pitu itary</w>
piri de-induced</w>
pirenzep ine</w>
pin prick</w>
pi g</w>
physici ans</w>
phthal m
phosphat ase</w>
phenyle phr
phenomen on</w>
phenobarbit al</w>
phenobarbit al.</w>
phen otyp
pharmaco kine
ph ot
ph or
pg/ ml</w>
persist ed</w>
peroxid ase</w>
perid ol</w>
pericardi al</w>
perform ance.</w>
per im
per ce
pepti de
peptide (1-
peptide(1- 4
pentylene tetraz
pentazoc ine-induced</w>
pent one</w>
penicill in</w>
pen ia,</w>
pen et
pel v
pe o
patient s'</w>
path ways</w>
path om
path ies</w>
particip ated</w>
part um</w>
paraly sis.</w>
par i
pari et
par am
param ed
pall id
pallid us</w>
paclitaxel ,</w>
pa rent</w>
pa re
pa in:</w>
pa ediatric</w>
p sy</w>
p ram
p h</w>
p et
p en</w>
p ect
p ast</w>
p anc
panc reati
p an
oxid ation</w>
oxic ity</w>
ox orub
ox carb
oxcarb azepine</w>
ove mb
ovemb er</w>
outcom es.</w>
out patient</w>
out .</w>
out -
ous -
ous- infusion</w>
ou gh</w>
other s</w>
ot otoxic</w>
ostig mine</w>
osteo poro
osmol ality</w>
osar coma</w>
os or
osor b
os ome</w>
os mo
osmo tic</w>
orth otopic</w>
orth o
organ ophosph
or me
or all
or =
or .</w>
opi ate</w>
open- labe
op tical</w>
on to</w>
on ly,</w>
on atal</w>
omas ti
om otor</w>
olog y.</w>
olog ists</w>
oli go
oler ance</w>
ol ute</w>
ol es
ol -
ol )</w>
ocy tic</w>
ocy tes.</w>
ocor tico
ocor tical</w>
ochond rial</w>
occur .</w>
oc tramine</w>
oc rit</w>
oc alce
oc al</w>
obut yric</w>
obser ved,</w>
obj ect</w>
ob vious</w>
ob ses
o- infected</w>
o ventricular</w>
o urable</w>
o side</w>
o plas
o ge
o der
o .</w>
normal- salt</w>
norep inephrine.</w>
nor adrenergic</w>
non- competitive</w>
non compl
noncompl i
no vel
no e
noe a</w>
no de</w>
nitroglycer in.</w>
nitrendi pine</w>
nit ros
nigh t
nifedi pine</w>
ng/ ml</w>
newbor ns</w>
neutro penia</w>
neutro penia,</w>
neut rophil</w>
neurotransmit ters</w>
neurotransmit ter</w>
neurolep tics.</w>
neurolep tic-induced</w>
neuro active</w>
nephroli thiasis</w>
neph ritis,</w>
neg atively</w>
necro tic</w>
necess it
ne ar</w>
nat urally</w>
n utritional</w>
n u
n mol/
n ess.</w>
n er</w>
n as
nas al</w>
n ar
n R
nR H</w>
n M</w>
n M)</w>
n ,</w>
my oton
my oclon
mut ants</w>
musc le.</w>
mun ic
muco sal</w>
muco sa</w>
mt DNA</w>
morph ometric</w>
mor al</w>
month s)</w>
month s).</w>
mon o-infected</w>
mol ind
molind one</w>
modul ators</w>
modul ating</w>
modul ate</w>
modi fy</w>
modi fication</w>
modi fi
model s.</w>
model s,</w>
mo stly</w>
mo fur
mofur -induced</w>
mmHg ;</w>
mmHg .</w>
mm Hg</w>
ml ).</w>
ml ),</w>
mitochondri a</w>
mis sed</w>
minim ize</w>
minim ally</w>
min ox
min o
min ated</w>
min (-1
midd le</w>
mid pontine</w>
microscop y</w>
micrograms/ m
micrograms/m L)</w>
micrograms/ kg</w>
micrograms/ kg/
microgram/kg/ min</w>
microgram s.</w>
microgli a</w>
microg/side )</w>
microangio pathic</w>
micro injected</w>
micro globul
microglobul in
micro g</w>
micro dialysis</w>
mg/m 2.</w>
mg/m (2
mg/kg/ day,</w>
mg/day )</w>
mg/K g</w>
mg/ d</w>
mg/ 24</w>
metri f
metopro lo
metoc lop
metoclop ram
methyl ergon
methyl dopa</w>
meth octramine</w>
meth i
methi azole</w>
metaboliz er</w>
metabol ized</w>
met ry.</w>
mes enchymal</w>
mening e
meninge al</w>
men ,</w>
memor y.</w>
memor y,</w>
membran e.</w>
mellit us.</w>
meflo quine</w>
medull a</w>
mechanism (
mechanism( s)</w>
mechanis m,</w>
measure ments</w>
measure d.</w>
meas urable</w>
me pivacaine</w>
me -
marg in</w>
man ip
man age</w>
mali an</w>
malform ations</w>
mal es,</w>
mal a
maint aining</w>
magnit u
mac ular</w>
mac a
maca que</w>
mTo R</w>
mT c
mTc -
mTc- glucar
mTc-glucar ate</w>
m us</w>
m urine</w>
m um
m e</w>
m ation</w>
m app
m am
mam malian</w>
lymph ocytic</w>
lymph ocyte</w>
lun it
lunit razepam</w>
loz eng
lop inavi
lopinavi r/ritonavir</w>
lop ido
long ed</w>
long -
logra m</w>
log ists</w>
lofen ac</w>
local ized</w>
local ize</w>
local ization</w>
loc i</w>
loc ation</w>
loc ally</w>
load ing</w>
lo st</w>
lo bular</w>
lit termat
lind ane</w>
lin k</w>
lin ed</w>
lim b
li ver.</w>
li pi
li gn
lign oc
li d</w>
leuk in</w>
leu covor
let on</w>
less er</w>
leng th</w>
le tion</w>
le mon</w>
lat ency,</w>
lat encies</w>
lamivud ine.</w>
lac rim
lac k
lack ing.</w>
labe ling</w>
l- arginine</w>
l is
l ine,</w>
l in</w>
l der</w>
l actin</w>
kidne ys.</w>
kg roun
kg -
kg- 1.
k i
ki logram</w>
k es</w>
k ac
k ),</w>
junc tional</w>
judg ement</w>
ju venile</w>
j usti
j ection</w>
iz es</w>
iz ed.</w>
iti s.</w>
iti es,</w>
it ochondrial</w>
it ing</w>
ist er
ister na
issu es</w>
isoflur ane</w>
ishe d.</w>
ishe d,</w>
isch aemic</w>
irrit ability,</w>
ir ar
irar ub
ir CRF</w>
ip yridam
ip ),</w>
intub ation.</w>
intraperitone ally</w>
intramuscul arly,</w>
intrader mal</w>
intra vitreal</w>
intra ventricular</w>
intra vascular</w>
intra hepatic</w>
intoxic ation,</w>
interac tion.</w>
interac t</w>
inter ru
inter leukin</w>
inter ference</w>
institu tion.</w>
inser ted</w>
ino genicity</w>
inhibitor s,</w>
inhibitor .</w>
ing ual</w>
infrequ ently</w>
infrequ ent</w>
inform ed</w>
influ x</w>
inflam mation</w>
infec tions</w>
infarc tion,</w>
inf ilt
inf ant,</w>
ineur in-
ineurin- inhibitor</w>
ine- associated</w>
ine ff
ine :</w>
ine ),</w>
induc ed
indol ent</w>
indo methac
indic ator</w>
ind u
ind ings</w>
ind ed</w>
increas ing
incontin ence.</w>
inclu des</w>
incid ent</w>
inc ubated</w>
in ess,</w>
in direct</w>
in dex
in ating</w>
in adequate</w>
impro ving</w>
implant ed</w>
impa ir</w>
immunosup pression</w>
immunohisto chemist
immunohisto chemical</w>
immun ostaining</w>
immedi ate-
immediate- release</w>
imag es.</w>
im mo
il ine</w>
il d</w>
ig n</w>
ifosf amide,</w>
ide a</w>
ide -induced</w>
ide -
id azol
ic ulation</w>
ia )</w>
i.p. ),</w>
i. e.</w>
i ved</w>
i v
i sian</w>
i pheral</w>
i atro
i als</w>
i =
i )</w>
hypo plastic</w>
hypo methylation</w>
hypo activity</w>
hyperprolactine mia</w>
hyper ammon
hyper activity.</w>
hyp ocalce
hydrox ylase</w>
hydrochlor ide,</w>
hydro gen
hydro cortisone</w>
hydro brom
hum an
human s.</w>
hospital ization</w>
hospit alized</w>
homogen ates</w>
ho me</w>
histor ies</w>
histor ic</w>
highligh ts</w>
high- grade</w>
high- frequency</w>
hi rsutism</w>
hex ach
hepatoc arc
hepatocarc inogenicity</w>
hepati tis
hepat o
hepar in,</w>
hemorrh age,</w>
hemoly sis.</w>
hemoglobin ,</w>
hemo dialysis</w>
hemo di
hemat ological</w>
heal th</w>
he ter
havi oral</w>
hapto globin</w>
haemorrh ages</w>
haemoly tic</w>
ha z
h ind
h ar
h and,</w>
h and
h .</w>
gynec omasti
gy rus</w>
gu n</w>
grow th.</w>
gres sive</w>
great est</w>
grav is</w>
granulo cyto
gran ules</w>
gran ule</w>
gra fts</w>
gra ded</w>
go al</w>
gn ant</w>
gly bur
glutam at
glutamat ergic</w>
glucocortico id</w>
glomerulosclero sis.</w>
glomeruloneph ritis,</w>
glo bu
globu s</w>
gli oblast
gener ation,</w>
gene- targeted</w>
gene sis,</w>
gen it
gen es</w>
gen e,</w>
gen cy</w>
gen ce</w>
gen -
gen- independent</w>
gamma-HCH ,</w>
gamma- amin
gamma-amin obutyric</w>
gamma ENaC</w>
gall stones,</w>
ga ve</w>
g/d l,</w>
g yrus,</w>
g s,</w>
g rypo
g ang
g an
gan ax
g ain
g .,</w>
fur an
func tions</w>
func tions.</w>
fu coid
fron totemporal</w>
frequ ency,</w>
frequ enci
frequenci es.</w>
frac tional</w>
frac tion
form ation.</w>
fo rearm</w>
fluores ce
fluoresce in</w>
fl ut
fix ed
first- line</w>
fin ished</w>
fibro sis.</w>
fib rous</w>
